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Poly(amido amine) (PAMAM) dendrimers have shown potential to carry 
poorly absorbed drugs across the intestinal barrier and into systemic circulation, 
reducing the need for intravenous injections. Much of the in vitro transepithelial 
transport of PAMAM dendrimers to date has been investigated using Caco-2 
monolayers which lack the microvilli morphology and enzymes present in isolated 
intestinal tissues. In addition, a challenge in predicting oral absorption is 
establishing a correlation between transport across rodent and human intestinal 
tissues. This dissertation focused on investigating the transepithelial transport of 
PAMAM dendrimers across rat and human isolated intestinal tissues. 
Permeability values in isolated tissues were compared with those across Caco-2 
cell monolayers. Results indicate a difference in transport of PAMAM dendrimers, 
morphological changes and transepithelial electrical resistance between Caco-2 
cell monolayers, rat and human intestinal tissue models. A relatively high 
transport rate across the tissues, given the macromolecular nature of PAMAM 
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1.1 Oral drug delivery 
Carrier based drug delivery has been used to improve the 
pharmacokinetics and biodistribution of small molecule drugs.1 Polymeric carriers 
particularly have been used to enhanced drug uptake at the site of action and 
minimize off-target effects.2 Water soluble polymer-based drug delivery can 
improve the safety of therapeutically active compounds with intrinsically poor 
water solubility and high toxicity.3 Nanomedicines such as polymers and 
liposomes have shown promise in altering the intracellular accumulation and oral 
permeability of drugs.4,5 Important targeting agents such as antibodies and 
peptides can be conjugated to delivery vehicles making such carriers useful for 
targeting sites of disease.6 
Many anticancer therapies are limited by poor water solubility and dose-
limiting toxicity.7 Conjugation of chemotherapeutics to macromolecular water 
soluble carriers such as poly(ethylene glycol) and N-(2-
hydroxyproply)methacrylamide (HPMA) copolymers can improve their 
biodistribution by increasing the drug concentration in cancerous tissue due to 




reduced offsite release of the drug are basis for polymer utility in drug delivery.9 
Additionally, many chemotherapeutics have low water solubility and poor 
oral absorption limiting their delivery by the intravenous route.10 This requires the 
patient to be present at the hospital for recurring visits, with significant direct and 
indirect costs.11 Attachment of poorly soluble drugs to water soluble polymers 
can enhance solubility, but the macromolecular structure of most polymers limits 
dosing to intravenous routes.12 Strong patient preference for oral formulations 
and the significant advantages of polymer therapeutics provide rationale for 
development of oral polymeric drug delivery systems.10 An oral polymer 
therapeutic has the combined advantages of increased water solubility, 
enhanced delivery to the site of action, a more flexible dosing regimen and 
reduced need for hospital procedures.13 
Oral drug delivery is challenging due to the harsh chemical and enzymatic 
environment of the intestinal tract.14 The human gastrointestinal tract is efficiently 
designed to limit the absorption of macromolecules.14,15 Intestinal gastric pH can 
reach levels as low as one, while proteolytic enzymes (such as trypsin) and 
metabolic enzymes (such as cytochrome P450’s) continuously degrade 
functional pharmaceuticals into kidney clearable content, not to mention efflux 
proteins, bile salts and food bolus which can hinder or alter pharmaceutical 
absorption.16–18 Therapies designed for oral delivery must pass through the low 
pH of the stomach, withstand various enzymes released into the chyme and 





Poly(amido amine) (PAMAM) dendrimers have been studied for the oral 
delivery of poorly absorbed compounds.4 PAMAM dendrimers are a class of 
hyperbranched water soluble carriers that have shown potential in increasing the 
absorption of both conjugated and entrapped drugs.19,20 These dendrimers are 
synthesized through the step-wise addition of ethylene diamine and methyl 
acrylate forming repeating layers termed generations.21 Each subsequent 
generation increases in diameter linearly, but increases in number of surface 
groups exponentially.22 Thus a generation 4 (G4) dendrimer has 64 surface 
groups and a 4nm diameter while a G5 dendrimer has 128 surface groups and a 
5nm diameter. These surface groups can be modified with positively charged 
amine groups, neutral hydroxyl or negatively charged carboxyl groups.23 In 
addition, various drugs targeting ligands and imaging agents can be attached to 
dendrimers making them a potential multifunctional drug delivery vehicle.24 
Many studies of PAMAM dendrimer intestinal penetration have been 
performed to date. In most of these studies, Caco-2 cell models were used to 
evaluate permeability and epithelial toxicity of the dendrimers.20,25–32 Dendrimer 
permeation across Caco-2 is a function of the generation, concentration, and 
incubation time.27 Mechanistic studies into the routes via which PAMAM 
dendrimers can penetrate the intestinal epithelium show that specific 
pharmacologic endocytosis inhibitors reduced the flux of G3.5 PAMAM 
dendrimers across Caco-2 monolayers.26 Other work showed that PAMAM 
dendrimer transport across Caco-2 cells was clathrin, dynamin and energy-




opening, as evidenced by occludin staining and increased mannitol transport.29–
31,33,34 Dendrimer permeability across Caco-2 monolayers appears to be via a 
combination of the transcellular and paracellular route. These studies have 
provided an initial understanding of dendrimer intestinal transport, but have 
limitations of Caco-2 cells such as the lack of mucous layers, intestinal 
morphology and in vivo enzyme levels, present in the human intestinal tract.35–38  
Indeed the discrepancy between permeability results in vivo and Caco-2 
monolayers has become more apparent with further research.19,29,39 Previously it 
was noted that concentrations as low as 0.1mM of amine terminated G4 PAMAM 
dendrimers caused a reduction in transepithelial electrical resistance (TEER) and 
increased mannitol transport across Caco-2 monolayers.29 On the other hand, 
permeability data observed in CD-1 mice indicated no increase in mannitol 
permeability or tight junction opening when PAMAM dendrimers were 
administered orally at concentrations of ~2mM and ~7mM for G4-NH2 and G3.5-
COOH, respectively.19 This concentration is almost 100 fold higher than “toxic” 
Caco-2 concentrations and still no significant changes in epithelial morphology or 
mannitol permeability have been noted. These discrepancies have led us to 
evaluate the permeability of dendrimers across isolated intestinal tissue models 
using the Ussing the chamber technique. 
The rationale for the use of isolated tissue models is that they provide 
higher fidelity of permeability results to human absorption than other models (i.e., 
Caco-2, parallel artificial membrane permeability assay (PAMPA), etc.).40 




drug absorption. Caco-2 cells have additional limitations including lack of 
intestinal enzyme levels and mucous layers.41 In vivo studies in animals are 
feasible, but doses can be diluted in the gastrointestinal tract, causing 
concentrations to vary and making transepithelial transport difficult to quantify. 
Also, in vivo results generally include first pass metabolism and tissue distribution 
that make transepithelial transport difficult to quantify. Rationale for the use of 
isolated intestinal tissue using the Ussing chambers includes the ability to control 
concentration, which can be variable in vivo due to dilution of intestinal contents. 
Also an advantage of Ussing chambers is the ability to reduce the quantity of 
animals required for experiment compared to in vivo studies. Finally, isolated 
tissue models have a higher ability to predict human absorption especially when 
using human tissues.40,42 Isolated intestinal tissue in Ussing chambers provides 
an alternative model that can be used to evaluate the potential of PAMAM 
dendrimers for oral drug delivery. 
Because most macromolecules have low permeability through the 
intestinal tract, additional penetration enhancers have been used to aid in their 
transport. Specifically peptide penetration enhancers (PEP) have been 
hypothesized to aid in the penetration of PAMAM dendrimers across the 
intestinal barrier.43 The benefit of PEP over other penetration enhancers is their 
ability to specifically modulate an opening of the tight junctions in the intestine, 
without causing toxicity to the epithelial tissue.44–47 C10 fatty acids, commonly 
used as penetration enhancers to enhance permeability cause significant 




in lactate dehydrogenase (LDH) release and histological damage and 
simultaneously modulates the opening of tight junctions for oral drug delivery.43 A 
one-month subchronic intranasal dosing of penetration enhancing peptides to 
rats showed no significant elevation of IL-1α or TNF-α and no damage to 
epithelial membranes.49 Likewise, other arginine rich sequences showed no 
additional toxicity or immunogenicity in cells, in animals nor in clinical trials.50,51 
The lack of toxicity to epithelial layers and simultaneous increasing penetration of 
macromolecules make PEP ideal for use in conjunction with PAMAM dendrimers 
for oral drug delivery without inducing toxic effects.  
A specific PEP with potential in macromolecular delivery is the P640 
peptide which has the specific amino acid sequence of RRVEVKYDRRKKR 
(single letter amino acid abbreviations are used) which modulate myosin light 
chain phosphatases leading to an increase in activated myosin light chain and 
the opening of tight junctions.51–57 The disruption of interaction of the myosin light 
chain phosphatase (MLCP) with myosin light chain (MLC) leads to the 
unregulated phosphorylation of MLC. MLC is constitutively dephosphorylated by 
MLCP, but when MLCP is inhibited ZIP kinase activity causes the 
phosphorylation of myosin light chain (MLC) to increase, leading to cellular actin-
myosin contraction.52,53 The contraction of the actin-myosin filaments in intestinal 
epithelial cells leads to the contraction of the perijunctional ring and the opening 
of tight junctions. The opening of these junctions allows drug delivery agents to 
pass through the paracellular space.58 The potential of these PEPs to induce 




suitable for delivery of macromolecules such as dendrimers.59  
 
1.2 Aims and scope of this dissertation 
The global hypothesis of this dissertation is that investigation of PAMAM 
dendrimer transport through insolated intestinal tissue can predict human 
absorption. The ultimate goal is to discover if PAMAM dendrimer permeability 
across the intestinal tissue is sufficient for use as an oral drug delivery carrier.  
This work encompasses the quantitative assessment of dendrimer 
permeability across isolated tissue models. Chapter 2 provides a review of the 
challenges of oral drug delivery with nanoparticles and the current models of 
intestinal absorption. The current clinical achievements of oral drug delivery 
using nanotechnology are summarized in this Chapter and published 
elsewhere.60 Chapters 3-5 contain work adapted from previous publications.61–63 
These chapters cover research that is aimed at assessing the differences 
between various transepithelial transport models such as Caco-2 monolayers, 
rat, and human isolated intestinal tissues. Chapter 6 provides conclusions and 
future directions of this research. In addition, an attempt was made to assess the 
intestinal permeability of PAMAM dendrimers in combination with peptide 
penetration enhancers. The results of these studies, included in Appendix A, are 







1.3 Specific aims 
Aim 1: To investigate the transepithelial transport of PAMAM dendrimers 
across rat isolated intestinal tissue in an Ussing Chamber set up. 
Rationale: Dendrimer transport needs to be evaluated in isolated tissue 
models to compare differences between Caco-2, isolated tissue and in vivo 
models. 
Hypothesis: Dendrimer transport is predicted to be significantly higher 
than similar sized fluorescein isothiocyanate (FITC)-dextrans and free FITC 
controls in isolated rat intestinal epithelium. A corollary hypothesis is that 1mM 
concentration of dendrimers do not cause significant epithelial morphological 
changes.  
In Chapter 3, the innate permeability of fluorescently labeled dendrimers 
(G3.5, G4) was assessed across rat jejunum. Histology and transepithelial 
electrical resistance (TEER) was examined to assess dendrimer effects on 
epithelial morphology and integrity.14 C-mannitol transport was monitored to 
assess tight junction modulation. These studies demonstrate that PAMAM 
dendrimer transport is significantly higher than free FITC controls in isolated rat 
jejunal tissue.61 1mM intestinal concentrations of G3.5 and G4 dendrimer were 
not found to cause changes in TEER, mannitol or morphology to the isolated 
epithelium. 
Aim 2: To investigate the regional transport of PAMAM dendrimers across 
isolated rat intestinal tissue and Caco-2 monolayers.  




transport of PAMAM dendrimers aids in determining the location of maximum 
absorption in the intestinal tissue. 
Hypothesis: PAMAM dendrimer intestinal transport is predicted to be 
greater in the jejunal region than the colonic region in isolated rat intestinal 
tissues. 
In Chapter 4, the permeability of PAMAM dendrimers G3.5 and G4 was 
assessed in rat colon and jejunum using the Ussing chamber technique. 
Transepithelial transport across these tissues was compared with permeability 
across Caco-2 cell monolayers. Morphology and integrity of the epithelial barriers 
was investigated using histopathology, measurement of TEER and mannitol 
transport. Results indicate that PAMAM dendrimer permeability is greatest in 
isolated jejunal tissues.62 
Aim 3: To investigate the transepithelial transport of PAMAM dendrimers 
across isolated human intestinal tissue. 
Rationale: Isolated human tissue has a strong correlation with human 
fraction absorbed and thus can be used as a predictive marker for PAMAM 
dendrimer bioavailability in humans.  
Hypothesis: Dendrimer permeability in human isolated intestinal tissue is 
predicted to be less than dendrimer permeability in rat isolated intestinal tissue. 
To address this aim we assessed PAMAM dendrimer generations 3.5 and 
4 regional transport in human colon and jejunum for the first time, as well as the 
regional permeability of mannitol in the presence of various concentrations of 




dependent effect of dendrimers on human intestinal epithelial morphology was 
evaluated. The permeability of dendrimers between isolated human, isolated rat 
and Caco-2 models was investigated. Results demonstrate that dendrimer 
permeability is sufficient for the oral delivery of potent drugs.63 
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The objective of nanoparticle and polymer therapeutics is to control the 
spatiotemporal release and distribution of incorporated drugs to improve safety 
and efficacy for patients.1 Specifically drug delivery technology can alter a drug's 
solubility, absorption, metabolism, elimination and biodistribution. This strategy 
can enhance the therapeutic index of the free drug by reducing toxicity and 
increasing efficacy. Additionally, many of these systems can be attached to 
imaging agents, drugs, and targeting ligands making them multifunctional drug 
delivery vehicles.2 Examples of drug delivery carriers include nanoparticles, 
polymers, micelles and liposomes.3–6 
Polymer-drug conjugates were first conceptualized in 1975 by Ringsdorf.7 
In this concept, a pharmaceutical molecule is covalently conjugated to a carrier 
through a degradable linker which can release the drug at the site of action. 
Properties of the carrier such as composition, molecular weight, architecture, 
surface charge and linker chemistry can be tailored to maximize efficacy and 
                                                          
1 Note-Parts of literature background reprinted with permission from Hubbard, D.; 
Brayden, D.; Ghandehari, H. In Handbook of Nanobiomedical Research; 
Frontiers in Nanobiomedical Research; World Scientific, 2013; Vol. Volume 3, pp 
153–202. Copyright 2014 World Scientific. 
15 
 
minimize off target release. 
Nonetheless, many of these polymeric delivery systems are limited to 
parental injections, due to low absorption through the intestinal route (Table 
2.1).8 Oral administration of pharmaceuticals has long been the preferred route 
compared to parenteral injections. The benefits of the oral route include flexible 
dosing, higher patient compliance and reduced health care costs.9 Many small 
molecules and biologicals have limited oral bioavailability due to low solubility, 
limited stability in the GI (gastrointestinal) tract as well as the low and variable 
permeation.10,11 These challenges form the basis of the design of 
nanopreparations for oral delivery.12 Oral nanopreparations have been 
investigated for improving the bioavailability (F) of various drugs such as 
heparin,13 enalaprilat,14 tobramycin,15 and antitubercular drugs.12,16,17 
Nanopreparations may enhance solubility, increase stability and absorption, and 
control spatiotemporal release.10 To date several nanopreparations have been 
approved by regulatory agencies for use in the clinic as oral dosages (e.g., Élan's 
Nanocrystal® technology).18 
The long standing need for the oral delivery of proteins and peptides has 
been recognized.19 Nanoparticle polymeric drug carriers have been viewed as 
possible formulations to improve oral bioavailability of such molecules.20,21 For 
example in the case of insulin, the human small intestine mesenteric blood 
delivers nutrients and drugs into the hepatic portal vein which makes oral delivery 
of insulin more physiologically relevant given that the liver is its primary target 








































































































































































































































































































































































































































































































































































































































































































































































































Many active small molecular weight drugs have poor oral absorption and 
solubility.22 Poorly soluble drugs may often have low or variable permeability 
across the intestinal epithelial barrier making dosing difficult to predict. 
Nanopreparations have been investigated for improving pharmacokinetics of 
poorly soluble drugs and poorly permeable drugs.18 Compared to intravenous 
administration, in oral delivery a delayed time to maximum plasma concentration 
(tmax) and a lower peak plasma concentration (Cmax) are observed. These 
attributes can facilitate a more flexible dosing regimen as well as decreased risk 
of infection from intravenous lines in chronic patients. 
Oral delivery of poorly soluble and permeable drugs has been facilitated 
by use of penetration enhancers23,24 and microparticles.25–28 Permeation 
enhancers have been used to improve transport across the epithelial barrier, 
while microparticles have been used to protect drug molecules from the harsh 
gastrointestinal environment. Depending on composition, nanoscale structures 
can potentially carry out both of these important functions aiding in oral drug 
delivery.20,29  
 
2.2 Physiological barriers to nanopreparations  
for oral delivery 
Clinical success for nanopreparations has been difficult due to the 
inherent physiological environment of the gastrointestinal tract. The intestines are 
designed to break down and absorb proteins, carbohydrates and lipids into 
component formats.11 Orally delivered drugs have to survive the stomach acidic 
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environment, the renin and pepsin enzymes, and the pancreatic enzymatic 
activity of the small intestine. In addition to these biological barriers, the drug has 
to be able to traverse across the intestinal epithelium.11,30 
Many drug compounds are hydrophobic in nature and hence poorly 
soluble in aqueous environments. Many of the drugs of biopharmaceutics 
classification systems (BCS) class II or class IV category require significant 
formulation in order to enhance their solubility. Nanopreparations can be used to 
solvate these drugs and to create greater drug exposure to the absorption site of 
the targeted organ.31,32 The dimension and shape of the delivery system can also 
have a significant effect on dissolution rate in the intestinal tract and subsequent 
oral bioavailability.10,33–35 
An important note for oral nanopreparations is that the stomach secretions 
can reach a pH level as low as 1. This pH can denature or hydrolyze many 
exposed proteins or other acid labile linkers, thus making the stomach milieu a 
formidable chemical barrier to oral formulations.11 On a related note, stomach pH 
can rise as high as 7 in the fed state.36 This can influence release from enteric 
polymer-coated delivery systems, such as Eudragit®, which are often used in 
order to protect acid or pepsin susceptible materials in solid dosage forms from 
degrading in the stomach. Another consideration is that the pH level of the small 
intestine ranges from 6.6±0.5 to 7.5±0.4.11,37 
Particle transit time varies based on region and size.38 Other physiological 
factors also affect transit time. The transit time from the stomach to the 
duodenum depends on the type of content in the stomach and the amount of 
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time since previous food intake. During fasting the stomach to duodenum transit 
time for saline is only 12 min, but with a large meal can take as long as 4 h.39 The 
carbohydrate portions usually arrive in the small intestine first while the fatty 
portions arrive last. Liquids can bypass the solid portions of the meal and enter 
the duodenum rapidly.40 Therefore, the time for an oral nanopreparation to reach 
the small intestine can be drastically affected by the contents of the stomach, and 
the body's state of fasting. This can be critical, if for example, in cases where an 
oral drug is stable for only 2 h but the transit time to the small intestine takes up 
to 4 h. Generally, like most nutrients and drug molecules, nanopreparations are 
not absorbed in the stomach, but more distally in the small intestine or colon. 
Some nanopreparations may not even reach the absorptive surface in an intact 
form. 
The actual flow speed of chyme through the small intestine is 
approximately 1-4 cm per min.40 Bile salts help bicarbonate to neutralize acid in 
fluid emerging from the stomach into the duodenum, but their primary role is to 
emulsify fatty contents. They are actively reabsorbed via the ileal bile acid 
transporter and returned to the liver for reuse.39 Bile salts can affect oral dosage 
forms by changing the properties of nanopreparations that are formed from 
micelles or surfactants. Pancreatic juice also delivers proteases, lipases, and 
carbohydrases, essential for further digestion in the small intestinal tract.41 These 
enzymes can cause degradation or denaturation of proteins, DNA and other 
labels or linkers that potentially have role in stabilizing an oral nanopreparation. 































































































































































































































































































































































































































































































































































































































































































































































































Mucous layer interactions can also interfere with absorption.42 A thick 
layer of mucus is secreted from the inner surface of the stomach protecting it 
from its acidic contents. Thinner layers coat the small and large intestine 
lubricating bolus food transport and protecting the delicate microvilli. This 
mucous can block nanoparticles from penetrating the intestinal wall, or provide a 
high turnover reservoir for temporary attachment and release.  
Monoglycerols, fatty acids, and glycerol from food diffuse through the 
epithelial membrane into the local cells where they are reassembled to 
triglycerides. These triglycerides are formed into small droplets of approximately 
150µm in diameter called chylomicrons. The chylomicrons are then transported 
by the golgi complex to the basolateral side of the cell and are exocytosed. The 
chylomicrons enter the central lacteal flow and are carried from the lymphatic 
system to vena cava to be injected back into the systemic circulation. This route 
through the lymphatic system can potentially be exploited for lipid based 
nanoparticle oral absorption.43 
A formidable challenge to oral delivery is the first pass metabolism effect 
in the liver. The intestinal blood flow drains into the hepatic portal vein and then 
enters the liver. Here a host of metabolic enzymes and phagocytic cells reside 
that can sequester nanopreparations and their cargoes. Intact nanopreparations 
are generally limited to <5% entering systemic circulation when orally delivered.44 
Variables operating on the physiological environment such as state of fasting, 
disease and enzymatic content of the intestines can affect the oral absorption of 
these systems. Nevertheless, nanopreparations can potentially be conferred with 
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characteristics that increase gastrointestinal regional residence time, enable 
transepithelial transport, and optimize pharmacokinetic parameters.45 
 
2.3 Tight junctions 
Epithelial cells along the surface of the intestine are joined by intercellular 
tight junctions. These junctions between cells are formed by a variety of proteins 
including claudins and occludins. Unless transported by another transcellular 
mechanism, these proteins form a 'belt' around the epithelial cell, sealing off the 
majority of hydrophilic molecules from passage into the blood stream.46 
Nanopreparations of ~1–3nm47,48 or smaller may penetrate through tight 
junctions without modifying intestinal physiology. Many nanopreparations with a 
larger diameter open tight junctions, facilitating their transport.20,49 Endocytic 
mechanisms, such as clathrin and caveolin mediated pathways contribute 
significantly to nanoparticle uptake.50,51 
Tight junctions have a range of pore sizes in different intestinal regions.52 
The molecular regulation of these junctions is also becoming better understood. 
It has been postulated that these junctions can open and close the intracellular 
space in a time dependent manner.53,54 While the tight junctional areas only 
account for 0.1–0.01% of the surface area of the intestinal tract (approximately 
200–2000cm2), their potential impact on oral nanopreparations should not be 
overlooked.11,48,55 Modern research places more emphasis on penetration 
enhancers that modulate tight junctions with reduced adverse effects.52 The 
permeability of nanopreparations may be significantly increased by the use of 
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targeted protein penetration enhancers for tight junction proteins. 
 
2.4 General principles of oral bioavailability 
The general principles governing what is orally bioavailable is an area of 
continuous research.56–61 Many factors affect amount of the compound that 
passes the intestinal epithelium and reach systemic circulation. These include 
partition coefficients (Log P, Log D), pKa, molecular weight/volume, aggregation, 
particle size and pH of the lumen and surface of the epithelium at the site of 
action. Physiological factors also play a role including state of anesthesia, blood 
flow, absorptive surface area, enzymes and membrane permeability. In short, to 
effectively evaluate an oral nanotherapy, it is important to use methods that have 
all the physiological and biochemical properties of human tissue, low variability 
between experiments, unbiased results, with comparable passive and active 
transport.62 This challenge can be difficult based on the use of various animal 
and cell culture models for studying oral bioavailability of drugs, but these models 
form the basis for current comprehension of nano-bioavailability. 
 
2.4.1 Mathematical evaluation of oral medicines 
The extent of bioavailability is termed F for fraction of AUC compared to 






where AUCIV is equal to the plasma area under the curve profile for the IV 
administered drug and the AUCPO is equal to the plasma area under the curve 
profile for the orally administered drug. This fraction can vary between 0 and 1 
and is generally <0.05 for orally delivered nanopreparations.44   
In order for a compound to achieve high oral bioavailability it must have a 
high apparent permeability defined as: 
 
Papp=(dQ/dt)/(A/C0) .......................... (Equation 2.2) 
 
where A is the area of the permeable membrane (cm2), C0 is the initial 
concentration in the intestine and dQ/dt is the time rate of the appearance (or 
flux) of the drug from the donor side (typically the basolateral side of the intestinal 
epithelium). The Papp equation comes from the equation for diffusion as notably 
established by Fick. Fick’s first law (J=-D∙δφ/δх), where J is flux, D is the 
diffusion coefficient, δφ is the concentration gradient and δх is the spatial term, 
can be reduced to the equation for flux with constant temporal and spatial 
arrangement. J=-P(c2-c1), where J is the membrane flux of the compound, c2 is 
concentration on the basolateral membrane and c1 is the apical concentration. 
When calculating the apparent permeability the c2 term can be assumed to be 0, 
since we have limited concentrations on the basolateral side throughout the 
experiment. This results in the equation J=P∙c1. Rearranging we achieve J/c1=P 
where P has units of cm/s, J has units of mol/(cm2∙sec) and c1 can equal 
mol/cm3. The J term is generally split into the time rate appearance of compound 
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on the basolateral surface (dQ/dt) in units of mol/sec, and the surface area (A) in 
units of cm2 to give the final equation: P=(dQ/dt)/(A∙c1). This form of the equation 
is based on the assumption that the basolateral side and apical side of the 
solutions do not vary significantly from start of the experiment. In practice we 
keep the variation of the apical and basolateral side to <10% of the starting 
concentration. Typically a compound with good oral bioavailability has a flux over 
10×10-6 cm/sec through the intestinal tissue while a compound with medium 
bioavailability has a permeability between 1-10×10-6 cm/sec and a compound 
with low bioavailability has a permeability <1×10-6 cm/sec. 
 
2.4.2 Models of the intestinal tract 
Four principal types of intestinal absorption models have gained 
prominence in the field of oral drug delivery: in vitro, ex vivo, in situ and in vivo. In 
vitro models such as parallel artificial membrane permeability assessment 
(PAMPA) and Caco-2 cells are commonly used for screening and ranking of drug 
permeability.63 Ex vivo systems include isolated tissue models and everted 
intestinal sacs. In situ models include the rat intestinal isolation model, where a 
segment of the intestine is cannulated and filled with a probe solution. In vivo 
models range from animal gavage in rats to oral dosing to humans in clinical 
trials (Table 2.3).  
The most prominent in vitro method used for both preliminary drug 
permeability and high throughput screening is the Caco-2 model. Derived from 























































































































































































































































































































intercellular tight junction upon maturation. They also contain a host of CYP 
enzymes as well as human P-gp proteins.63 Although some of the protein 
expression levels in Caco-2 cell lines are vastly different from those in human 
small intestine, the model provides sufficient data for ranking drug 
permeabilities.64–66  
Models that use isolated animal tissue are referred to as ex vivo because 
they contain living tissue in a ‘organotypic’ environment with all resident cell 
populations (enterocytes, calciform cells, lymphocytes, etc.) as well as mucus 
layers and intestinal morphology.63 The Ussing chamber set up is an ex vivo 
model which involves mounting intestinal tissue between two half cells for 
permeability testing (Figure 2.1). Sample volumes are loaded on the apical and 
basolateral side of the tissue and aliquots are taken at time intervals thereafter.67 
The tissue is oxygenated to avoid decreased tissue viability and to increase 
sample homogeneity through mixing. The tissue viability using this method 
ranges from 3-4 h depending on the region of interest.68 Cell culture, animal, and 
human tissue has been used in Ussing studies.69,70 The tissue can be tested via 
AgCl electrodes for epithelial resistance to Cl- ion transport. Large libraries of 
pharmaceuticals have been tested in Ussing chambers using human isolated 
tissue and found a strong correlation to exist between human fraction absorbed 
and isolated tissue permeability.71 This model can perform multiple studies using 
a single animal in an effort to reduce and refine animal experiments. 
The everted gut sac method involves removing a 2-3 cm length of 









faces outward. The tissue is subsequently filled with oxygenated buffer (for 
prolonged tissue viability) and tied off at both ends. This model has the 
disadvantage of permeability results being normalized to total protein content of 
the tissue (not exposed surface area as are Ussing chambers) and the variation 
inherent in protein content analysis.63 
The in situ model involves permeability results performed in anesthetized 
animals through a laparotomy, and gently pulling the desired portion of the 
intestinal tract out of the abdomen for cannulation. Once the dose is injected the 
desired region of the intestine can be tied off at one or both ends of the tract for 
the duration of the study. This method has the advantage of controlled 
concentrations in the intestinal lumen, but is limited in duration and throughput. 
The most frequently studied model in vivo is the rat since it maintains 
higher fidelity to human paracellular permeability and metabolism characteristics 
than dog.72 Rats do have restrictions in dose volume and tend to overestimate 
(provide false positive) results.73 Rats have a higher gastrointestinal pH than 
humans. The pH of chyme in the stomach of humans can be as low as 1-2 while 
rats exhibit pH levels as low as 3-5.72 The microbial contents of the rat and 
human are different with different populations at different regions of the intestinal 
tract. The human stomach and upper small intestine are basically absent of 
microbial life, while rats have large population in the stomach and upper small 
intestine (due to the high pH of the stomach). The rat intestine includes a cecum 
which is much reduced in humans. Additionally The overestimation of 
nanoparticle transport by isolated rat jejunum may be due to the wide difference 
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in number of follicles per cm2 of intestinal tissue (0.03 follicles/cm2 versus 2.1 
follicles/cm2 in human and rat small intestine, respectively).74,75 In general rat 
intestinal tissue is more permeable to macromolecules that human intestinal 
tissue as shown in this body of work and in others.76 
The ability to successfully deliver cargoes in humans is not easy to 
extrapolate from small animal work and in vitro studies, which is the rationale to 
perform research in human isolated tissue models. Much of this work focuses on 
isolated intestinal permeability mounted in Ussing chambers. Isolated tissue 
intestinal models have more physiological characteristics of the human intestine 
than Caco-2 cell cultures.77 Morphology, enzyme levels, mucous layers and 
cellular function and heterogeneous cell type are more accurately represented in 
isolated tissue models than in Caco-2 cell monolayers.30 Also, the throughput of 
isolated tissue models is higher than in vivo work. This provides rationale for the 
use of isolated tissues to further study the potential of PAMAM dendrimers for 
oral drug delivery.  
 
2.4.3 Correlation with human fraction absorbed 
It can be argued that the most important aspect of selecting an intestinal 
model to study is the correlation with human absorption. The purpose of intestinal 
absorption models is to ultimately extrapolate those results to man in order to 
assess clinical absorption of the compound. Many correlations have been 
established over the years between in vitro, ex vivo and in vivo results to better 
predict human absorption.71,77–82 Apparent correlations between Caco-2, isolated 
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rat tissue, in situ rat tissue and human isolated tissue experiments have been 
established. (Table 2.3) Caco-2 correlations exist, but have a very narrow region 
between 0 and 100% absorption prediction, making results highly variable. Caco-
2 interlab variability appears to be very high and therefore standardization is 
difficult. Isolated rat intestinal tissue has a much larger prediction band between 
0 and 100% absorption and has been found to have a better fit (R2 of 0.95 vs R2 
of 0.90 for rat and Caco-2, respectively).  
One of the largest correlation studies performed is the correlation between 
isolated human intestinal tissue and human fraction absorbed.71 In this study a 
correlation was established between isolated human tissue permeability and 
human fraction absorbed was produced with combined results from three 
separate labs and 159 human donors and >60 drugs. The established correlation 
curve for human fraction absorbed had an R2 of 0.85, and a p-value of <0.01. 
This study is a helpful addition in the prediction of human fraction absorbed in 
that it did not seek to exclude drugs based on low or high permeability 
classification, but included a broad range of pharmaceuticals with various 
transporter functions. Two of the pharmaceuticals excluded from the correlation 
were actively effluxed from the intestine by p-glycoproteins. Since this study used 
trace levels of the compounds for permeability assessment, these compounds 
showed erroneously low permeability (the efflux proteins are saturated at higher 
concentrations resulting in a high human absorption at clinical doses). Thus 
human isolated tissue has been established as an effective way to predict human 
transport and fraction absorbed for small molecular weight pharmaceuticals at 
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clinically relevant doses.  
For macromolecular oral drug delivery systems the correlation with human 
isolated tissue still generally holds true, with compounds such as poly(ethylene 
glycol), ovalbumin, and dextrans and fitting into the correlation curve exactly as 
predicted.76,83,84 Limitations of the model may come from compounds that are 
actively endocytosed or effluxed, such as was mentioned previously. Interactions 
with tissue mucous, and other epithelial layers may modify transport further. 
These changes may or may not be reflected in the permeability through the 
tissue and the prediction of fraction absorbed. Thus prediction of fraction 
absorbed for nanoparticles and polymers may be limited based on the correlation 
established in human isolated tissue, but is not entirely inaccurate. 
 
2.4.4 Penetration enhancers 
Most polymers and nanoparticles have low oral absorption necessitating 
the use of penetration enhancers to achieve therapeutically relevant levels. 
Penetration enhancers have been studied to increase the oral bioavailability of 
nanotherapies, especially proteins.85 Generally penetration enhancers work by 
two methods: either chemical alteration of the macromolecule itself or 
formulations to exploit physiological or nonphysiological transport mechanisms.86 
Some of the major classes of penetration enhancers include chitosans, N-
acylated amino acids, surfactants, steroidal detergents, acylcarnitines and 
protein penetration enhancers (Table 2.4). 












































































































































































































































































































































































































































effects, but those are limited to approximately a twofold enhancement ratio for 
hydrophobic molecules.87 Additionally higher concentrations of PAMAM 
dendrimers have negative impact on epithelial morphology thus limiting their 
dose.88 Protein penetration enhancers on the other hand have shown no damage 
to epithelial barriers at higher doses. 89,90 A combination of protein penetration 
enhancers with dendrimers may avoid further damage to epithelial barriers while 
still enhancing their permeability. Thus a combination of PAMAM dendrimer 
formulated with protein penetration enhancers may be optimal for polymeric oral 
drug delivery. 
 
2.5 Types of nanopreparations 
The general principles governing the physiochemical properties of drug 
molecules that influence oral absorption is an active area of research.56–61 For 
nanopreparations, many factors can influence their absorption into the systemic 
circulation. These include particle composition, pKa of the material components,  
molecular weight, particle aggregation, particle size, pH, inherent stability of the 
particle, and surface charge.11 Physiological parameters can also vary based on 
state of anesthesia, fasting or disease. These physiological parameters modify 
the permeability of the membrane, surface area of the epithelium and mucous 
layer properties.39 These barriers have led to experimentation with a wide variety 
of nanoparticles for drug delivery (Table 2.5). 
The single most formidable barrier for nanopreparations to enter the 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































penetration enhancers include surfactants, chelating agents, bile salts, cationic 
and anionic polymers, acylcarnitines, and fatty acids.11 Generally, penetration 
enhancers work by physiological alteration of the epithelium to exploit transport 
mechanisms.91 Exploited transport mechanisms can be subgrouped into methods 
that disrupt the structural integrity of the epithelial layer, decrease the mucous 
viscosity, open tight junctions or increase membrane fluidity.11 Penetration 
enhancement principles assume a sufficient quantity of therapeutic agent and 
penetration enhancers at the site of absorption.92 This formulation goal can be 
difficult to accomplish due to variance in intestinal motility, gastric emptying and 
dilution factors in the gastrointestinal tract. Approximately 9.0L of fluid enters the 
small intestine each day, of which only about 2.0L is food and liquid ingested, 
giving a dilution factor > 4 fold.39 Nanoparticles can increase effectiveness of 
penetration enhancers by carrying them to the intestinal barrier and releasing 
them in a site specific manner to aid in particle absorption. Penetration 
enhancers, which have been reformulated into nanopreparations, aid 
bioavailability by increasing the local delivery of drug and enhancer. Makhlof et 
al. showed that a solution of co-delivered penetration enhancer spermine and 
nanoparticles was not as effective as nanoparticles encapsulating spermine in 
delivery of salmon calcitonin to rats.93 This provides rationale for encapsulating 
penetration enhancers such as chitosan and glycerides into nanoparticles 





2.5.1 Chitosan nanoparticles 
Chitosan has been widely researched for uses as both a nanopreparation 
and as a permeation enhancer in oral delivery.99–101 Chitosan is made from 
deacetylated chitin. Chitosan is a linear polysaccharide made of varying ratios of 
N-acetyl-D-glucosamine and D-glucosamine groups. It has an extremely high 
oral LD50 in mice of 16 g/kg orally (as nontoxic as sugar and salt).102 Primary 
amines and hydroxyl groups on chitosan can be modified to attach functional 
moieties. Chitosan has a positive charge at pH <6.5 due to the fact that it has 
free amino groups with a pKa of 6.1. Native chitosan has limited solubility at pH 
>7.103 Lack of charge and solubility of chitosan at neutral and basic pH levels 
cause it to be less effective as a penetration enhancer in the small intestine 
where pH can rise above 6.5. Modifications were thus developed to increase 
chitosan's solubility in the small intestine. Thiolated chitosan, quaternization of 
the primary amine with methyl groups (trimethylchitosan), PEGylated chitosan, 
N-succinyl chitosan and carboxymethyl chitosan derivatives have all been 
evaluated for oral delivery.104–107 Some of these have been used in oral 
nanopreparations with varying effects. 
Chitosan nanoparticles have shown to cause a decrease in TEER 
(transepithelial electrical resistance) and increase in FITC-dextran permeability in 
Caco-2 models.108,109 The mechanism by which they open tight junctions appears 
to be through F-actin and ZO-1 protein depolymerization.110 The penetration 
enhancing effect of chitosan solutions appears to be dependent on the molecular 
weight and degree of deacetylation of the chitosan. The best results for 
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absorption enhancement have been observed for chitosans having 65% 
deacetylation and a >170 kDa molecular weight in rat small intestine. This 
information can be useful for the preparation of nanoparticles as well.111 Chitosan 
nanoparticles have exhibited particular advantages over free chitosan solutions 
in that they are endo- and transcytosed and better protect cargo drugs.112  
Substantial research has been conducted on the oral delivery of insulin 
using chitosan as a nano-carrier.101,113–115 Many of these have utilized the mild 
ionic gelation techniques that can maintain insulin's three-dimensional structure. 
In one example, nanopreparations were synthesized by ionotropic gelation in the 
size range of 250–400 nm using 88.9% deacetylated chitosan.96 When dosed to 
diabetic rats, hypoglycemic blood glucose levels were maintained for >15 h. The 
relative oral bioavailability of the insulin was as high as 14.9%.96 
In order to increase the bioavailability of insulin, modified chitosan has 
been studied. The basis for modification is to maintain the charged nature of the 
amine groups in order to increase the penetration enhancing effects at neutral 
and basic pH. For this purpose quaternized chitosan nanoparticles have been 
developed.116 Trimethyl- and dimethyl chitosan showed enhanced insulin delivery 
in rats over chitosan solutions and unmodified chitosan nanoparticles during 
colonic delivery.116 These were estimated to improve bioavailability based on the 
increased solubility at neutral and basic pH. The nanoparticle delivery showed 
the highest effect when free chitosan solutions and chitosan nanoparticles were 
admixed prior to delivery. 
Active targeting of chitosan using peptides has also been investigated for 
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goblet cell delivery. Trimethylchitosan nanoparticles with goblet cell targeting 
peptides (CSK) showed improvement over trimethylchitosan insulin delivery.117 In 
Caco-2/HT29-MTX co-cultures, transepithelial transport was increased using 
CSK peptide-conjugated nanoparticles. Similar nanoparticles loaded with insulin 
showed increased relative bioavailability compared to subcutaneous injection in 
rats for targeted versus nontargeted nanoparticles (5.66% vs. 3.69%, 
respectively).117 This study provided the rationale for active targeting of chitosan 
nanopreparations in oral delivery.  
Combinations of nanopreparations have been studied for improved oral 
delivery of therapeutic cargoes with chitosan. An example is alginate: a 
biodegradable anionic polymer composed of β-D-mannuronic acid and α-L-
glucuronic acid. The anionic properties of alginate make it ideal for complexation 
with chitosan as this increases their stability. Combinations of chitosan and 
alginate also aid in oral insulin delivery by facilitating the complexation of the 
protein and nanoparticle.100 Nanoparticles formulated by ionotropic pregelation of 
an alginate core followed by chitosan complexation with the surface were ~750 
nm in diameter and obtained an insulin loading capacity of 9.9%.49 When dosed 
orally to diabetic rats they showed a significant hypoglycemic effect from 8–14 h 
with decreased levels lasting for 18 h. The duration of hypoglycemia was longer 
than in previous studies with chitosan nanoparticles.96,113 Insulin solution mixed 
with the nanoparticles showed only a minor decrease in blood glucose levels, 
highlighting the importance of encapsulation in the nanoparticles.49 The relative 
bioavailability of insulin in this nanoparticle formulation was 7% versus 
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subcutaneous insulin.49  
Some of the most promising results in vivo involved the encapsulation of 
insulin in chitosan, facilitated by the incorporation of glutamic acid residues and 
zinc (a known complexing agent for insulin118). Chitosan-γ-glutamic acid 
nanoparticles of diameter ~197 nm showed a loading efficiency of insulin of 57%. 
They reduced blood sugar levels by 60% for >10 h in streptozotocin induced 
diabetic rat models.20 The benefits of these chitosan-glutamate nanopreparations 
were improved solubility at a range of pH values. Unfortunately these systems 
degraded in vivo in the neutral-basic pH of the intestine causing premature 
release and degradation of the protein.20 In order to overcome this problem 
Sonaje et al. lyophilized the nanoparticles and inserted them into enteric 
capsules. This approach increased the oral bioavailability of insulin to ~20%. 
However conclusive evidence in large animals and man is necessary.119–121  
Inhibition of intestinal proteolytic enzymes has been explored for 
enhancing oral delivery of proteins.122 Chitosan alone is insufficient to inhibit 
trypsin and carboxypeptidases.123 Further development of chitosan antienzyme 
technology led to the conjugation of ethylenediaminetetraacetic acid (EDTA) to 
chitosan, but these conjugates also were not effective against trypsin, 
chymotrypsin and elastase.122 Competitive enzyme inhibitors (i.e., papain, 
chymostatin) were used in conjunction with EDTA-chitosan to slow degradation 
of encapsulated insulin. 40–60% of insulin remained after 4.5 h when including 
inhibitors compared to 90% degradation without.124 This combination highlights 
the potential role of enzyme inhibitors in oral nano drug delivery. 
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Chitosan-DNA complexes have been studied for the purpose of improving 
transfection efficiency via the oral route. Attempts have been made to optimize 
transfection efficiency based on charge ratio, chitosan molecular weight, 
endosomes escaping peptide conjugation and DNA concentration.125 These 
studies have resulted in formation of stable DNA-chitosan nanoparticles of 
approximately 100–500 nm in size (102kDa chitosan). However they produced 
expression levels 200 fold less than Lipofectamine on Cos-1 cells. Surprisingly, 
when instilled in an upper rabbit small intestine, chitosan showed better 
transfection than lipid based DNA carriers. 
Chitosan nanoparticles have also been studied for oral anti-
hypersensitivity gene therapy. In one of these systems, cDNA for peanut antigen 
was encapsulated in monolithic high molecular weight chitosan (390 kDa) 
nanoparticles. The particle size was assessed by TEM and appeared on the 
order of 150–300 nm in size. The testing of anaphylactic shock scoring after oral 
administration of chitosan-DNA complexes, carrying the peanut antigen, showed 
that this nanopreparation was able to reduce hypersensitivity response to peanut 
antigen in vivo.126 Lack of clinical translation of these systems may be related to 
low transfection efficiency due to mucous entrapment of the chitosan 
nanoparticles occurring in the intestine. Uptake of the chitosan nanoparticles and 
subsequent release of the DNA may give higher transfection rates than pre-
endocytosis release. The mucous adhesion of the chitosan may increase local 
concentrations of the target gene at the epithelial surface, but limit uptake of the 
nanoparticles themselves, thus limiting transfection.127 Improved transfection 
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efficiency will probably be needed to merit further development and translation. 
In spite of significant efforts for developing oral chitosan based delivery 
systems they have not yet reached clinical trials.100,127 A major concern may be 
the toxicity of chitosan. In vitro blood coagulation studies have shown that 2% 
solution of unmodified chitosan (126kDa) causes a 40% decrease in coagulation 
time with heparinized blood, whole blood, and defibrinated blood.128 Varying 
degrees of quaternization have showed modulated in vitro toxicity, bringing to 
light the importance of evaluation of novel chitosan derivatives. This effect is 
illustrated by the study in MCF-7 cells where increasing charge density 
(quaternization) exhibited a decreasing IC50 at an exposure time of 6 h.129 Future 
clinical development may require extensive toxicity evaluation of chitosan which 
could be a possible reason for lack of translation.130 Also the ability of chitosan to 
increase oral bioavailability may not be sufficient. Difficulties with scale up of 
production may be another source of concern. Despite these problems, the ease 
of synthesis and penetration enhancing effects of chitosan have prompted 
continued research of the material. Novel modifications, such as thiol-protected 
chitosan, hold promise for future improvement. 
 
2.5.2 Poly(alkyl cyanoacrylates) (PCA) 
Poly (alkyl cyanoacrylates) have been extensively used for drug 
delivery.131,132 These polymeric systems are made from the common acrylate 
monomer system with an additional cyanate group. The use of PCA in drug 
delivery is based on their ability to encapsulate small hydrophobic drugs and also 
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proteins.133 PCA was the first polymer nanoparticle used for oral delivery of 
peptides.133 This landmark study using insulin set the stage for many other 
nanoparticle-peptide oral drug delivery studies.134 PCA has also been shown to 
improve the oral bioavailability of small molecular weight drugs.135,136 A large 
number of studies have been done on the delivery of proteins and drugs using 
PCA demonstrating its versatility as a drug delivery agent.137,138 PCA is 
considered bioerodable due to the hydrolysis of its side chain ester moieties 
producing the corresponding alkyl alcohol and poly(cyanoacrylic acid).139–141 In 
the gut, pancreatic esterases are able to degrade PCA nanoparticles and release 
their cargoes. This hydrolysis proceeds at variable time rates depending on the 
side alkyl chain length. PCA above molecular weight 10,000 Da is probably not 
excreted from the body.142  
PCA nanoparticles can be synthesized in acidic water solutions with 
strong mixing and added surfactants for stabilization.137 Polymerization begins 
immediately upon the addition of the monomer to any solution containing 
nucleophilic groups (i.e., OH). The rate of reaction can be slowed by lowering the 
pH of aqueous polymerization solutions. The size of the nanoparticles can be 
adjusted between 40 and 200 nm based on the concentration of surfactants used 
in pure PCA nanoparticle synthesis. The combination of different polymers 
(chitosan, dextran) can change the size of the end product as well as the zeta 
potential. For in vivo work all products need to be maintained sterile during 
polymerization. Heat, gas, filtration or radiative sterilizations are not appropriate 
for PCA nanoparticles.137 Nanocapsules (nanoparticles with hollow cores) can be 
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formed using PCA. These can be either water or oil-cored to carry cargoes. 
Isobutylcyanoacrylate (IBCA) nanocapsules have been used for oral delivery of 
insulin in streptozotocin diabetic rats (see Figure 2.2 for structural differences of 
PCA monomers). Results obtained showed hypoglycemia of 65% lasting for up 
to 18 days after administration. Delivery to the ileum showed the greatest 
hypoglycemic effect using the IBCA nanoparticles.143 This demonstrates the 
ability of nanoparticles of IBCA to deliver proteins orally, but other results have 
shown lack of efficacy. Nanoparticles of IBCA entrapping calcitonin underwent 
slow degradation of the peptide in simulated intestinal fluids, but in vivo 
absorption was not significantly increased.144 Initial studies by Lowe et al. 
showed that rapid release of calcitonin occurred and little protection from 
intestinal proteins was afforded by IBCA nanoparticles.144 
Nanoparticles using PCA have also increased the oral bioavailability of 
small molecular weight drugs. Hexylcyanoacrylate (HCA) nanoparticles have 
shown to increase the oral bioavailability of vincamine in rabbits.136 The oral 
bioavailability of vincamine in HCA nanoparticles was increased from 25% to 
40% when the drug was entrapped. Also the oral bioavailability of mitoxantrone 
was increased by incorporation in poly(butylcyanoacrylate) nanoparticles. This 
result could be explained by the local release of the drug next to the epithelial 
barrier following the mucoadhesion. 
Poly(isohexyl cyanoacrylate) (PIHCA) nanoparticle formulations have 
been investigated for the delivery of cyclosporine A. Nanoparticle delivery could 





Figure 2.2. Chemical structures of common PCA derivatives. Methyl 
cyanoacrylate (MCA), ethyl cyanoacrylate (ECA), n-butyl cyanoacrylate 
(nBCA), isobutyl cyanoacrylate (IBCA), isohexyl cyanoacrylate (IHCA), octyl 
cyanoacrylate (OCA), isostearyl cyanoacrylate (ISCA), hexadecyl 




in vivo study of PIHCA nanoparticles in mice showed a 13 fold increase in 
bioavailability of the nanoparticle over an emulsion of cyclosporine A.145 The 
study also showed a greatly reduced liver AUC as well as reduced kidney 
exposure to the drug. This study demonstrates the further ability of these 
systems to avoid reticuloendothelial uptake. 
Poly(butyl cyanoacrylate) (BCA) loaded with calcitonin showed a 45% 
decrease in calcium levels compared to control intravenous injection following 
oral administration to rats. Absorption enhancers such as deoxycholic acid and 
sodium lauryl sulfate were also used to enhance permeability.146 
Specific properties of PCA nanoparticles can be modified in order to 
modulate interactions with mucous proteins. This can optimize absorption 
enhancing properties of nanoparticles and cargo release. Size and surface 
characteristics are the major properties that affect mucous interactions.147–149 
Other properties, including surface modification with other polymers such as 
large MW PEG and chitosan, can increase mucoadhesion.150 
Toxicity of PCA has been noted for shorter chain cyanoacrylates (methyl 
cyanoacrylate) in humans when used as a wound closure agent, and 
subsequently was replaced by longer chain cyanoacrylate adhesives.132 It has 
been reported that the degradation products of PCA could potentially be 
converted to formaldehyde through the inverse Knoevenagel reaction. This led to 
several reports attributing toxicity of nanoparticles to this mechanism.151–153 It has 
been postulated that this mechanism is too slow to compete with much more 
rapid metabolic pathways that degrade PCA.132,152,154 The results of an 
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intravenous phase III clinical trial of PIHCA nanoparticles for the purpose of 
doxorubicin delivery are of relevance (Livatag®, BioaAlliance Pharma, France). 
This trial was later suspended based on severe pulmonary adverse events.134 
This could have been due to aggregation of the nanoparticles, but the exact 
mechanism is unknown. Toxicity of these systems needs to be further addressed 
for intravenous and oral dosing.134  
 
2.5.3 Dendrimers 
Dendrimers were first described in 1978 by Fritz Vögtle and his group at 
University of Bonn.155 Since then a variety of these branched structures have 
been developed.156 Dendrimers are characterized by their hyperbranched 
structure resulting from repeating branches off of a central core atom. This 
branching results in a tree like structure, that forms a spherical or near spherical 
macromolecule with multiple sites for attachment at the surface (Figure 2.3).157  
Also the internal spaces remaining between the branched structure create loci for 
hydrophobic encapsulation of other drugs or nanoparticles in the core.158 This 
multifunctional surface and encapsulating core, combined with low polydispersity 
and prolonged plasma half-life make these polymers suited for drug delivery.6  
 
2.5.3.1 Poly(amido amine) (PAMAM) dendrimers 
PAMAM dendrimers have been evaluated for oral drug delivery.157 These 
dendrimers are synthesized through repeated Michael addition to the free 





Figure 2.3. Branching PAMAM dendrimers enable attachment of moieties to 
multiple surface groups or the encapsulation of molecules in the interior 
spaces. Reprinted with permission from M. F. Ottaviani, S. Bossmann, N. J. 
Turro, and D. A. Tomalia, Characterization of starburst dendrimers by the 
electron paramagnetic resonance technique. 1. Copper complexes in water 
solution, Journal of the American Chemical Society. 116(2), 661Ð671 (Jan., 




or carboxyl terminated surfaces. Full generation amine terminated (G1.0, G2.0, 
etc.) or half generation carboxyl terminated (G0.5, G1.5, etc.) dendrimers allow 
for modification of the surface charge and modulated toxicity profiles.160 PAMAM 
dendrimers were first shown to cross the gut mucosa in an everted intestinal sac 
model.161 Altering the termini can change the bioavailability of these dendrimer 
conjugates. These characteristics give favorable qualities for PAMAM dendrimer 
drug delivery. 
The potential of PAMAM dendrimers to permeate across the intestinal 
epithelial barrier was shown by Wiwattanapatapee et al.161 Using everted rat gut 
sacs it was observed that serosal transfer rate of anionic dendrimers was high 
(2.3–2.7 microL/mg protein/h) for G3 and G4.161 Transepithelial transport was 
observed to be dependent on a variety of factors including size, surface charge, 
concentration and incubation time.88 
PAMAM dendrimers have shown toxicity both in vitro157 and in vivo.160 
Caco-2 cell culture studies and CD-1 mice experiments showed that toxicity was 
generation, size, surface charge and incubation time dependent.160,162 Toxicity for 
PAMAM dendrimer surface groups ranks in the order of hydroxyl-
terminated<carboxyl-terminated<amine-terminated systems.163 Carboxyl 
terminated, G3.5 and G4.5 PAMAM dendrimers were cytotoxic using an LDH 
release assay from Caco-2 cells at concentrations higher than 10.0 mM whereas 
amine terminated dendrimers, G3.0 and G4.0, were cytotoxic at much lower 
concentrations (1.0mM). Concentrations of 0.01mM G4.0 were found to be non-
cytotoxic by LDH assay and visual inspection in Caco-2 cells.164  
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Orally dosed PAMAM dendrimers showed similar toxicity to intravenous 
injections of the same in CD-1 mice. At toxic doses, disseminated intravascular 
coagulation-like effect and fibrin degradation products with resultant intravascular 
coagulation and hemorrhage were observed. It was noted that the amine 
terminated dendrimers were more toxic than carboxyl terminated in CD-1 
mice.160 PAMAM dendrimer surface groups have been modified to reduce 
toxicity. PAMAM dendrimers with lauroyl chains attached to the surface have 
shown decreased toxicity and increased permeability across Caco-2 cell 
monolayers.165 Other surface modifications such as PEGylation, acetylation and 
FITC labeling have been observed to reduce toxicity and improve transport 
across Caco-2 monolayers.166–168 
Anionic dendrimers have been observed to open tight junctions and 
increase mannitol transport across Caco-2 cell monolayers. In the size range 
studied, larger dendrimers appeared to have a greater effect. Higher permeability 
of mannitol across Caco-2 cell monolayers was noted for G2.5, G3.5, and G4.5 
dendrimers, compared to smaller G-0.5, G0.5 and G1.5 dendrimers.169 
Fluorescently labeled G2 dendrimers showed increased permeation with 
increasing times ranging from 90 to 150 min in Caco-2 cell culture. It was also 
shown that the transport was energy-dependent with decreased permeability at 
4°C compared to 37°C.162 A portion of transport may be dependent on endocytic 
mechanisms. PAMAM dendrimers have been shown to be transported across 
Caco-2 cell monolayers via paracellular and transcellular routes.50,51,162,164,167 
The ability of PAMAM dendrimers to permeate the epithelial barrier and 
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enter systemic circulation was recently investigated.170 It was shown that 106,000 
Da G6.5 dendrimers were able to be absorbed orally in CD-1 mice. One mg/kg of 
radio-labeled G6.5 dendrimers were dosed by oral gavage to mice, and animals 
were sacrificed at 4 h. 9.4% of the macromolecular dose was found to be 
absorbed into the plasma after exclusion of unbound radio-label by size 
exclusion chromatography.170 This in vivo study shows promise for enhancement 
of bioavailability of highly potent drugs using PAMAM dendrimers.  
The potential of PAMAM dendrimers to increase transepithelial flux has 
been harnessed for the delivery of propanolol.165 Lauroyl modified dendrimers 
with 2–6 moles of lauroyl per dendrimer were attached to G3.0. The study 
showed increased transport of propanolol when lauroyl chains were attached 
compared to dendrimer and propanolol alone. The endocytosis inhibitor 
cyclosporin A did not decrease transport, but reduced temperature (4°C) did. 
This phenomenon may be based on the energy dependent endocytosis of 
PAMAM dendrimers. More studies are needed to evaluate the stability of 
dendrimer-lauroyl chain conjugates. 
PAMAM dendrimers have also been shown to increase the transepithelial 
transport of naproxen when covalently conjugated.171 The stability of the 
conjugated system to G0 dendrimers was dependent on the bond type with the 
amide bond being more stable than the ester. Using liver homogenate and 
plasma it was found that the amide conjugate was stable for up to 48 h. Further 
attachment of lauroyl chains increased permeability across Caco-2 cells.172 
PAMAM dendrimers have shown increased transepithelial transport of 
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anticancer compounds. Kolhatkar et al. complexed SN38 (7-Ethyl-10-hydroxy-
camptothecin) with PAMAM G4.0. SN-38 is a highly potent topoisomerase poison 
which has poor water solubility and dose limiting toxicity. The prodrug of SN38, 
CPT-11, is used in the clinic, but is 1000 fold less active than SN-38. 
Complexation or conjugations with dendrimers can potentially reduce toxicity and 
improve oral bioavailability. Complexation with dendrimers led to a 100 fold 
increase in transepithelial transport across Caco-2 cell monolayers. However the 
complex was not stable.173 Attempts to remedy this problem by covalent 
attachment were made.174 Stability of the conjugates of SN38 with carboxyl-
terminated G3.5 using glycine and β-alanine linkers demonstrated that the β-
alanine linkers are more stable. Transepithelial transport across Caco-2 cells was 
increased for both conjugates. Studies performed with these conjugates found 
reduced cytotoxicity compared to the free drug for both.175 Further studies with 
PAMAM dendrimers for delivery of small molecular weight drugs has been 
reviewed previously.157,163 
PAMAM dendrimers have major advantages over other penetration 
enhancers in terms of being able to covalently attached therapeutic drugs to the 
surface and increase their transport. Most other penetration enhancers only 
modify the epithelial border to increase transport. Dendrimers are a 
macromolecular drug delivery vehicle which add improved circulation time, 
passive targeting and solubility to covalently attached drugs.  
Some of the problems with clinical translation of PAMAM dendrimers may 
be associated with the batch to batch variability in synthesis. Low and variable 
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drug loading have caused problems associated with drug attachment. While 
some of these problems may be associated with finding appropriate solvent 
systems for hydrophilic dendrimers and hydrophobic drugs, other problems may 
arise from the altered pKa and reactivity of surface amine and carboxylic acids 
on dendrimers.  
PAMAM dendrimers may have an altered pKa and reactivity of surface 
amine and carboxylic acid groups. Surface groups have a tight spacing on 
dendrimers (approximately 0.78nm2 per group). Surface amines have been 
shown to fill outer perimeter space exceeding the packing limit of amines and 
forcing some groups inward.176,177 This may increase the pKa of surface amines 
forcing away excess protons and positive ions. Conversely, closely packed 
carboxylic acids on half generation dendrimers may have a lowered pKa due to 
the electron rich environment of many tightly packed COO- groups. This may 
influence conjugation chemistry and other techniques used to attach external 
groups. Specifically, the popular carbodiimide chemistry could be inhibited by the 
lack of protonated carboxylic acid groups on half generation dendrimers.178 
PAMAM dendrimers have potential to improve the bioavailability of poorly 
absorbed drugs. Toxicity of these polymers must be monitored in order to avoid 
systemic effects and local irritation. In addition linker chemistries need to be 
developed that are stable in the GI tract, during transport across the blood barrier 
and in the blood stream and allow release at the target site. Another barrier to 
translation of PAMAM dendrimers is challenge with scale up of the synthesis, 
which takes several reaction steps to produce.156 
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2.5.3.2 Poly lysine dendrimers 
Poly lysine dendrimers have been synthesized for improved stability and 
reduced synthetic steps (reduced cost) over PAMAM dendrimers.156 These 
dendrimers have also been studied for oral absorption. Florence et al. 
synthesized and characterized poly lysine dendrimers originating from glycine 
cores with lipid termini. Two and a half nm diameter dendrimers were chosen for 
dosing to rats at 14mg/kg and 28 mg/kg. A maximum of 3% of the tritiated 
dendrimer was found in the blood at 6 h.179 This uptake was not in excess of that 
for 50 nm latex beads. More studies are needed to investigate in detail the 
stability of poly lysine radiolabel conjugates in the GI tract, during transport and in 
the systemic circulation.  
 
2.5.4 Poly(lactic acid) (PLA) and poly(glycolic acid) 
(PGA) nanoparticles 
PLA and PGA have the unique advantages of being both degradable and 
resorbable. The two monomers can by copolymerized (poly(lactic-co-glycolic 
acid)) (PLGA) at varying feed ratios to customize the crystallinity and hydrolysis 
rate (Figure 2.4).180 Both nano- and micro- drug delivery have been studied using 
PLGA particulate systems. The biodistribution of the PLGA particles can be 
influenced based on the size of the particles. Particles that are >250–300 nm are 
predominantly taken up by the spleen, while particles that are several microns in 
diameter are taken up by the lung.181 PLGA nanoparticles have been shown to 










systems validating their use for oral drug delivery.38 Uptake into the intestinal 
tissue of the free nanoparticles was especially high for 100 nm PLGA particles in 
the ileum of anesthetized rats. It was noted that uptake was higher in Peyer’s 
patches compared to villous tissue. 
Increased absorption has also been observed using PLGA nanoparticles 
for oral delivery of drugs. PLGA nanoparticles were used for the purpose of 
administering antituberculosis drugs isoniazid, rifampicin and pyrazinamide 
orally.182 These nanoparticles had a size of 186–290 nm and showed an 
increased mean residence time (in the blood-plasma compartment) and 
bioavailability in guinea pigs. The levels of drug in the plasma were sustained for 
7–12 days when encapsulated, while the drug alone was only detectable for 24 
h. Guinea pigs infected with mycobacterium tuberculosis showed no signs of 
infection following administration of 5 oral doses of antibacterial loaded PLGA 
nanoparticles, compared to 46 doses of the free drug. This study shows promise 
for reducing dose frequency for the antituberculosis drugs.182 Improvements on 
this study were performed by attaching wheat germ agglutinin to the PLGA 
nanoparticles. Bioavailability and residence time were increased from 4–6 days 
to 6–7 days for rifampicin, and from 8–9 days to 13–14 days for pyrazinamide 
and isoniazid.183  
PLA-pluronic-PLA triblock copolymers have been used for effective oral 
insulin delivery.184 These nanopreparations were synthesized due to their 
vesicular nature and theoretical biocompatibility. The ability of these polymer 
combinations to encapsulate insulin was demonstrated. The release profile for 56 
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nm PLA-pluronic-PLA vesicles showed a biphasic pattern, with initial burst 
release and subsequent sustained release over a 4 h time period. Induction of 
hypoglycemia in rats was demonstrated by gavaging 50 IU/kg dose in vesicles 
which yielded a sustained effect for over >18.5 h.185 
PLGA nanoparticles have been covalently linked to RGD peptides for the 
purpose of increasing M cell uptake.186 These nanopreparations showed 
increased uptake in human M cell co-cultures. In vivo ovalbumin-loaded PLGA 
nanoparticles showed significant concentration in mice M cells and were able to 
elicit an immune response.  
Immune cell targeting is one of the goals of PLGA nanoparticle oral 
delivery. Previous work on oral vaccination against virulent strains of E. coli has 
been carried out in humans using microspheres. This has led to vaccine efficacy 
of 30% in early studies.187 Later, Katz et al. used PGA microspheres carrying 
CS6 antigen from enterotoxigenic E. coli, in order to induce immunity, but there 
was no apparent difference in response to the encapsulated antigen compared to 
the unencapsulated. While these were microparticles, their equivocal results may 
be the chief reason why PLGA particle systems have not been continued in 
further clinical trials for vaccine delivery. Other reasons why these systems 
appear to have been excluded from further clinical testing in oral delivery may be 
due to instability, lack of uptake from the intestine, instability of the antigen during 





2.5.5 Polymeric micelles 
Polymeric micelles represent a colloidal dispersion ranging from 5 to 100 
nm in diameter. They are generally composed of amphiphilic materials, which 
spontaneously self-assemble to form a hydrophobic core and hydrophilic corona 
in aqueous environments. This formation occurs when the concentration of 
amphiphilic material rises above the critical micelle concentration (CMC) and 
when the temperature of the system remains below the CMT (critical micelle 
temperature). The association of the amphiphilic molecules is based on the 
decrease of free energy of the system due to the loss of hydrophobic interactions 
with water molecules, and the reestablishment of the hydrogen bond network in 
water.190 Micelles are different from liposomes in that they lack an aqueous core, 
but instead maintain a hydrophobic core where poorly soluble cargoes (drugs) 
can be encapsulated. In the intestinal tract bile salts are believed to naturally 
form micelles aiding in fat digestion and transport.3,191,192 Micelles have been 
used in oral drug delivery and enhancement in Cmax, AUC0-24 and tmax of poorly 
soluble drugs in vivo.8,193 Polymeric micelles generally do not affect TEER.194 
Pluronic (poloxamer) micelles have shown potential for oral drug 
delivery.195 Pluronics are triblock copolymers made of a central hydrophobic 
chain of poly(propylene oxide) (PO) with two hydrophilic chains of poly(ethylene 
oxide) (PEO) on the outside. These can be tailored for specific hydrophilic / 
hydrophobic balance by customizing the length of the hydrophilic EO and 
hydrophobic PO portions of the polymer. Pluronics spontaneously form micelles 
above a critical micelle concentration in the range of 10–50nm.196 Pluronic F127 
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of average compositions EO99PO67EO99, showed increased oral delivery of 
genistein in rats compared to genistein powder.197 The plasma AUC was 3 fold 
higher at a dose of 4 mg/kg genistein in anesthetized rats (p> 0.5). The micelle 
particle size was on average 27nm. Pluronics inhibit P-gp efflux showing 
potential to aid in transepithelial transport.8 
The ability of micelles to improve bioavailability of small molecule drugs 
(BCS class II) were exhibited using monomethyletherpoly(oxyethylene glycol750)-
poly(caprolactone-co-trimethylene carbonate) (mmePEG750P(CL-co-TMC)) 
micelles and risperidone.198 Micelles, 20 nm in diameter (10% weight polymer 
solution), were dosed to rats exhibiting a 2 fold increase in risperidone 
bioavailability compared to risperidone solution. Tmax was extended by 3 h to 
match that of the radiolabeled micelle constituents. This correlation between drug 
and micelle concentration maxima suggests that the drug could remain 
encapsulated during transport. Drug half-life was extended 1.3 times showing a 
sustained release effect. 
The increased transepithelial transport of micelle encapsulated drugs 
remains controversial.194 Some evidence suggests that increasing concentration 
of micelles decreases transport of micellar components across the membrane. 
14C labeled mmePEG750P(CL-co-TMC) micelles showed decreased permeability 
across Caco-2 cells with increasing concentration of polymer.198 This could be 
due to passage of unimers and lack of passage of micelles, leading to saturated 
transport of unimers at or above the CMC. Opposing this report, poly(oxy 
ethylene cetylether hydroxyl propylcellulose) (HM-HPC) mixed with poloxomer 85 
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caused a 3 fold increase in permeability of cyclosporin A across Caco-2 cells.199 
It was hypothesized that increased solubility may be the primary reason for 
increased transport. In spite of opposing in vitro studies, transport of micellar 
components appears to be significant in vivo. Micellar components were 
observed to reach a bioavailability as high as 40% upon oral administration of 
mmePEG750P(CL-co-TMC) micelles to rats. These results validate the oral 
absorption of micellar components in vivo.198  
D-α-tocopheryl poly(ethylene glycol) succinate (TPGS), poloxomers and a 
variety of other common micelle components have shown inhibitory effects for P-
glycoprotein (P-gp) efflux pumps.194 This has provided the rationale for oral drug 
delivery using polymeric micelles. The mechanism by which TPGS inhibits Pgp 
efflux appears to be through allosteric modulation of the Pgp protein, while that of 
poloxomer appears to be through membrane fluidization and decreased ATPase 
activity.200,201 Increased transepithelial transport due to Pgp efflux is most 
pronounced at concentrations below the CMC, which is likely due to higher 
presence of the unencapsulated drug in solution.202,203 The exact mechanism of 
Pgp efflux inhibition by these micellar components is not fully understood.194 
The effects on Pgp efflux may be observed in an oral administration study 
of paclitaxel in micelles of poly(ethylene glycol) poly(2-(4-vinylbenzyloxy)-N,N-
diethylnicotinamide) (PEG-b-P(VBODENA)).204 Upon intraduodenal 
administration in rats of the paclitaxel micelle formulation (drug loading of 37.4 
wt%, 105–120 nm diameter), bioavailability was 12.4% compared to a previously 
reported oral bioavailability of Taxol® of 6.5%.205 The ability of the micelle 
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formulation to increase the bioavailability may be dually related to the increase in 
solubility of paclitaxel and the inhibition of Pgp efflux. 
For BCS class II drugs poor solubility is a significant concern that may be 
surmountable using micellar compositions. The physiochemical structure of 
micelles with the hydrophobic core and hydrophilic corona make them well suited 
for formulation of such drugs. Increases in solubility have been observed to be as 
high as 15,000 fold for paclitaxel.204 The ease of synthesis of these systems is 
also well suited for manufacture, in many cases requiring only simple mixing of 
components. Micelles for oral delivery have not yet been extensively investigated 
in vivo, likely due to interaction of bile salts and other food components with 
these systems leading to low stability.194 The bioavailability of drugs in micellar 
formulations may still be too low or too variable to merit clinical development.206 
 
2.5.6 Liposomes 
Oral delivery of liposomes has been investigated for the purpose of drug 
and protein delivery.188 Liposomes consist of an inner aqueous core surrounded 
by a membrane. Membrane components can be composed of naturally derived 
phospholipids such as egg phosphatidylethanolamine or 
dioleoylphosphatidylethanolamine (DOPE), phosphotidyl choline or phosphotidyl 
inositol.11 Oral liposomes have special requirements beyond intravenous 
liposomes due to the harsh gastrointestinal environment. Liposomes generally 
need to maintain stability in the gastrointestinal milieu and release their drug at 
the site of absorption. Liposomal systems can be unstable in the presence of bile 
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salts, phospholipids, lipases, acidic environments and other physiochemical and 
enzymatic barriers native to the gastrointestinal environment. Especially in the 
case of liposomes carrying small hydrophobic species that can easily precipitate 
in aqueous environments, the understanding of lipid metabolism and colloidal 
changes due to additional endogenous lipids can be important.207 
In spite of these difficulties, liposomes for oral delivery have shown some 
promising results. The oral delivery of insulin using bile salt sodium glycocholate 
and soybean phosphatidylcholine as liposome forming agents was evaluated in 
rats.208 These agents have both penetration enhancing and enzyme inhibiting 
effects. Sodium glycocholate liposomes showed a 5.7% and 11.4% insulin 
bioavailability in nondiabetic and diabetic rats, respectively. Hypoglycemic levels 
as low as 63% of control samples were achieved. Oral dosing of controls 
involving admixed liposomes and insulin (no encapsulated insulin) were done. No 
significant increase in blood insulin levels or hypoglycemic effect was observed 
for control admixed solutions.208 This confirms the importance of the liposome as 
a protective carrier for insulin. Also of note is that liposomes of size 2µm showed 
no significant hypoglycemic effect or insulin bioavailability, confirming the 
importance of nanoparticle size.208 This recent study highlights the positive 
effects of liposomes on oral drug delivery and represents a relatively high 
bioavailability compared to other studies with chitosan95,119,209,210 and 
liposomes.211 Mechanistic studies support the absorption of the liposome with 
cargo as opposed to free insulin solution. Higher bioavailability could be due to 
the better protective effect against proteolysis in the GIT. 
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PEGylated liposomes were also studied for oral delivery of human 
epidermal growth factor in rats.212 Dipalmitoylphosphatidylcholine (DPPC) 
liposomes carrying recombinant epidermal growth factor showed a 2.5 fold 
increase in AUC using liposomal formulations over growth factor solution. Gastric 
healing of ulcers was modulated using these liposomal carriers. 
Studies with PEGylated liposomes have been performed for oral 
vaccination purposes.213 PEGylated liposomes were observed to cause an 
effective mucosal immune response. The effect of lipid ratio on antigenicity was 
analyzed. It was observed that a higher relative amount of phospholipid dose 
(12.5µmol vs. 5µmol) for encapsulation of the antigen protein led to a higher (1.7 
fold) IgG response. On the other hand it was found that an IgA response was 
reduced by increasing the phospholipid dose.  
Despite these results, most attempts to orally deliver vaccines using 
liposomes have ended in failure.214 For example Orasomes™ were developed for 
oral delivery of drugs and also for targeting M-cells for vaccination purposes. 
These nanopreparations were initially promising based on the stable cross linking 
lipid components making them resistant to detergent disruption.189 In vivo studies 
demonstrated increased uptake in M-cells through the use of UEA-1 (Ulex 
europaeus 1) mouse M-cell targeting protein,215 but these systems did not 
advance to clinical trials.216 The reasons why these systems have been 
unsuccessful are probably multifaceted. Insufficient loading, irreproducible 
manufacturing, difficulties in scale up and low uptake by M cells may be causes 
of the lack of translation.188 
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While we still await a successful clinical outcome from oral liposomal 
delivery of drugs or proteins, future research should be focused on increasing 
permeability and absorption into systemic circulation. Higher loading and longer 
release profiles may also be critical for increased drug delivery to the site of 
action. Stability is also of importance and related to both of these aims. New work 
in the area of archaeosomes (liposomes made from lipids extracted from 
archaebacterias) could help achieve these goals, as they are based on non-
saponifiable lipids. Archaeosomes have shown 3.5 fold increased absorption of 
99technetium-diethylene triamine pentaacetic acid (DTPA) in rats over 
conventional liposomes.217 Other combination strategies using polymer coated 
liposomes could also aid in stability, release and drug loading goals. 
 
2.5.7 Solid lipid nanoparticles 
Solid lipid nanoparticles as drug delivery systems have been actively 
studied for many years.218 These systems are similar to liposomes, but use solid 
lipids instead of liquid, create a homogenous hydrophobic core, and can maintain 
stability for sustained periods of time in vivo.219  
These nanopreparations are generally composed of glyceride molecules 
manufactured easily through high pressure liquid homogenization or phase 
inversion temperature shifts.220 These lipids are usually of varying chain length 
because single size lipids may form highly crystalline particles and expel drugs 
from the interior regions. The heterogeneity of the lipid chains has found to be 
conducive to drug loading.218 Generally lipids such as caprylic acid or capric acid 
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can be used for these systems with PEG and small amounts of lecithin are added 
for stability. These compounds are currently used in oral, topical and parenteral 
administrations and are generally considered safe.219–221 
Oral administration of solid stearic acid nanoparticles coated with 
poloxamer 188 (mean diameter 196.8 nm, ζ-potential -69mV) loaded with 
camptothecin showed increased absorption in vivo compared to camptothecin 
solution. Interestingly the solid lipid nanoparticle formulation displayed a double 
peak, presumably from the initial burst release and subsequent sustained release 
from the particle core. Delivery of all-trans retinoic acid (ATRA) has been 
investigated by oral gavage in male rats.222 It was found that solid lipid 
nanoparticles increased ATRA oral bioavailability approximately 5 fold over 
ATRA solution. These studies provide the rationale for oral solid lipid 
nanopreparations for drug delivery. 
Cyclosporin A has also been dosed orally in solid lipid nanoparticle 
formulations.223–225 Microemulsions of cyclosporin have shown nephrotoxicity and 
variable bioavailability.225 Attempts have been made to overcome these problems 
using nanoparticles loaded with 20% cyclosporin. The lipid Imwitor was used with 
Tagat S (PEG-30 glyceryl stearate) and sodium cholate to stabilize the 
nanoparticles. The solid lipid nanoparticle formulation was found to eliminate the 
initial peak in cyclosporin blood concentration and exhibited sustained blood 
concentrations. 
Treatment of rats with insulin loaded solid cetyl palmitate lipid 
nanoparticles showed a hypoglycemic effect.113 These nanoparticles prepared by 
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solvent emulsification-evaporation were 350 nm in diameter and had a 43% 
loading efficiency. Poloxamer 407 was used to stabilize the nanoparticles. After 
oral administration to rats, a hypoglycemic effect or area above the curve (AAC) 
was 484 versus 260 for insulin loaded nanoparticles, and insulin alone, 
respectively. The hypoglycemic effect lasted for 24 h and was significantly lower 
than insulin control. 
Solid lipid nanoparticles formulated from glyceryl monostearate were used 
to encapsulate vinpocetine.226 These nanoparticles were studied for drug release 
and particle stability. Vinpocetine, which is normally highly insoluble, was stable 
in these nanoparticles for up to a year. Tween 80 and poly(oxyethylene) 
hydrogenated castor oil were used to stabilize the nanoparticles, but were also 
found to enhance the oral bioavailability of the nanoparticles. The nanoparticle 
formulation increased the bioavailability of vinpocetine significantly. For a more 
exhaustive analysis of types of therapeutic agents included into solid lipid 
nanoparticles readers are referred to a relevant review.219 
Mucosolvan™ (ambroxol) is the only solid lipid nanoparticle product that 
has reached the market to date for treatment of acute and chronic 
bronchopulmonary disease. (Boehringer-Ingelheim, Germany). Other products in 
this area, such as Rifamsolin™ which was in phase I clinical trials in 2005, 
appear to have been abandoned (AlphaRX now UMeWorld, Canada).227 The 
reason for the lack of further development of some solid lipid nanoparticle 
formulations appears to be instability in the gastrointestinal tract.228 Other 
problems associated with these systems could be the lack of sufficient 
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improvement of absorption to warrant clinical success. Future research into the 
use of solid lipid nanoparticle could focus on less degradable lipid formulations 
(such as the previously mentioned archaeosomes) and increased penetration 
enhancement.  
 
2.5.8 Nanosizing of standard formulations 
A large portion of both current drugs on the market and investigational 
pharmaceutical agents have low solubility in water.22,225 Nanopreparations have 
been able to increase the solubility of hydrophobic drugs by increasing the 
surface area exposure of the solid formulation. Reducing the size of solid 
pharmaceutical ingredients can increase the dissolution rate and saturation 
solubility of drug. This can be of critical importance for low solubility drugs. The 
increase in saturation solubility of the drug creates a greater local concentration 
gradient across the intestinal epithelium aiding in absorption. This has been 
shown to increase the oral bioavailability of several formulations (in addition to 
creating novel intellectual property for drugs coming off of patent). The theoretical 







∙ (S(Cs − Ct))……..………....(Equation 2.2) 
 
where dw/dt: Dissolution rate (mg/s), S: Effective surface area of the solid drug 
(cm2), Cs-Ct: Concentration gradient (mg/mL), Cs: Saturated concentration 
(mg/mL), Ct: Concentration of the solute at time t (mg/mL), h: Effective diffusion 
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layer thickness (cm), and D: Diffusion coefficient (cm/s). Dissolution rate is 
positively affected by increasing the surface area based on this equation. This 
can be achieved through reducing the size to nanodimensions. It has been 
observed that nanosizing can have a dramatic effect on the oral bioavailability of 
the drug in vivo. For example in an oral dosing of naproxen in rats the AUC0–240 
of the nanoparticle suspension was 125% that of the free solution.230 Indeed, one 
of the first reports to analyze the effect of nanosizing a formulation on oral 
bioavailability showed a 50–80% increase in bioavailability of phenylbenzoylurea 
derivative HO-221 by decreasing the particle size from 17µm to 450 nm in rats 
and dogs.231,232 
The demonstration of clinical successes using this solubilization of small 
molecules is the greatest of any oral nanopreparation category to date. A large 
number of pharmaceuticals have already been approved using the nanosizing 
technology (Table 2.6). Tricor sales alone have exceeded $1 billion, soundly 
placing this paradigm into mainstream pharmaceutical industry.233 The nano 
formulation showed reduced variability between fed and fasted states for the 
delivery of fenofibrate and allowed reduction in the dosage level. A variety of 
other products have progressed to clinical trials for oral delivery using this 
technology.45 Élan Pharmaceutical Technologies (now Alkermes, Ireland) has 
trademarked the methods used for creating nanosized pharmaceuticals as 
Nanocrystal™ while SkyPharma uses the term Dissocubes™.31,33 These 
nanoparticles are produced in a top down approach, where larger particles are 





















































































































































































































































































































































































































































































































and milling can be completed within a few h. Difficulties of nanosizing 
formulations include stabilization of the nanoparticles after synthesis. 
Stabilization is necessary because of the high surface energy created by the 
small size. If this surface energy is not tailored to the right range, Ostwald 
ripening or agglomeration can occur. The optimal ratio of stabilizer is usually 20:1 
to 2:1 and can include cellulosics, pluronics, polysorbates and povidones. 
Combinations of ionic and nonionic stabilizers are often used to decrease 
aggregation and Ostwald ripening. In spite of additional stabilizers the dispersion 
can be made into tablets, capsules and fast melts adding additional versatility to 
this approach.10,33  
This approach is limited to those drugs that are dissolution rate limited 
since nanosizing itself does little to increase penetration of the intestinal 
epithelium. Other problems that still exist for nanosizing technology include the 
empirical method of screening excipient stabilizers for each drug and lack of 
miniaturized processes supporting discovery. Future work into novel mechanisms 
of synthesis, such as spray freezing into liquid or evaporative precipitation into 
aqueous solution could aid in reducing particle size below 100nm. Patents for 
this technology will soon end, opening the door for other companies to take 
advantage of nanosizing drug formulations for insoluble molecules.233 Many 
small molecule drugs have yet to be tested for nanosizing effects, but the 
benefits may be well worth the cost.10,234 Choosing a system optimal for oral 
delivery among the mentioned materials must be based on requirements in size, 
loading, charge, toxicity and cargo. Nevertheless the fraction absorbed observed  
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for PAMAM dendrimers in mice, has given rationale for their continuing 
investigation in oral drug delivery.170,235 The fact that apparent permeability (Papp) 
generally decreases with increasing molecular weight, dropping to <5×10-6 cm/s 
at a molecular weight of 500 Da for poly(ethylene glycol), while 14 kDa PAMAM 
dendrimers have a Papp of >30×10-6 cm/s in Caco-2 is promising.167,236 Additional 
studies on the transepithelial transport of dendrimers in isolated animal and 
human intestine will aid in understanding the clinical potential of dendrimer oral 
drug delivery. 
 
2.6 Conclusion  
Oral administration of PAMAM dendrimers may be able to combine the 
advantages of polymeric drug delivery and simultaneously deliver drugs via the 
oral route. PAMAM dendrimers have been shown to enhance the solubility of low 
solubility drugs. Furthermore, PAMAM dendrimers have the ability to penetrate 
through the intestinal epithelium at high rates, making them optimal for oral 
dosing. The oral route of administration remains the preferred route for dosing of 
pharmaceuticals. Decreased stringency for production as well as increased 
patient quality of life are the driving forces behind manufacture of oral 
formulations.  
Estimation of PAMAM dendrimer oral drug delivery is largely based on in 
vitro models such as Caco-2 which lack human like properties such as mucous, 
transport proteins, metabolic enzymes and tissue morphology. On the other 
hand, isolated tissue models have these properties and have been shown to be 
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predictive of human fraction absorbed, especially when using human isolated 
tissue. Likewise, isolated tissue models have higher throughput than in vivo 
models and do not require expensive clinical trials in order to test human 
intestinal transport. 
Overall the goal of realizing dendrimer oral drug delivery may require the 
use of penetration enhancers to achieve high rate of absorption. While dendrimer 
penetration of the intestinal epithelium has shown to have damaging effects on 
the intestinal barrier, peptide based penetration enhancers have shown little 
effect on epithelial morphology. These enhancers have an ability to enhance 
macromolecular transepithelial transport. This has provided rationale for the use 
of peptide penetration enhancers in conjunction with PAMAM dendrimers to 
achieve a nontoxic oral drug delivery. 
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TRANSEPITHELIAL TRANSPORT OF PAMAM  
DENDRIMERS ACROSS ISOLATED 
RAT INTESTINAL TISSUE 
 
3.1 Introduction  
Polymeric drug delivery can improve solubility, biodistribution and 
bioavailability of insoluble and highly toxic drugs.1 Poly(amido amine) (PAMAM) 
dendrimers are a highly branched class of polymers that can increase solubility 
and intestinal permeability of drugs.2–4 These versatile carriers have multiple 
surface groups which can be functionalized with imaging agents, drugs, labels 
and targeting ligands.5–8 PAMAM dendrimers can also be surface-engineered to 
tune their toxicity and pharmacokinetic profiles, allowing them to be tailored for 
specific biomedical applications.9,10  
PAMAM dendrimers penetrate the intestinal barrier in vitro and in vivo, 
                                                             
1 Note: Reprinted with permission from D. Hubbard, H. Ghandehari, D. J. 
Brayden, Transepithelial transport of PAMAM dendrimers across isolated rat 
jejunal mucosae in Ussing chambers, Biomacromolecules, 2014, 15, 8, 2889-





suggesting a rationale for use in oral drug delivery.11–19 The oral route of drug 
delivery has the distinct advantage of increased patient compliance, reduced risk 
of needle-borne infections and improved pharmacokinetic profiles compared to 
parenteral dosing.20 Many chronic diseases including cancer treatments require 
years of regular injections, which could be circumvented if the drug was 
absorbed orally. Many other small molecules require injection due to their poor 
intestinal solubility and low or variable intestinal absorption, especially when the 
drug has a narrow therapeutic index. PAMAM dendrimers have shown to 
increase the intestinal permeability of camptothecin,21 propanolol,22 naproxen,23 
SN38,24 and silybin.25 This provides rationale for the development of PAMAM 
dendrimers as an oral drug delivery system for poorly absorbed drugs. In this 
chapter we evaluated the ability of PAMAM dendrimers to be absorbed through 
the isolated rat jejunal epithelium.  
Caco-2 cell cultures have been used for the majority of evaluations of 
PAMAM dendrimer transport through the intestinal epithelium.10,12–15,17,18,26,27 
Such studies provided analysis of dendrimer intestinal penetration and toxicities. 
They revealed that dendrimer permeation is a function of the dendrimer 
generation, concentration, and incubation time.18 These studies have also 
provided mechanistic insights into the routes via which PAMAM dendrimers can 
penetrate the intestinal epithelium. Previous work demonstrated that specific 
pharmacologic endocytosis inhibitors reduced the flux of G4 PAMAM dendrimers 
across Caco-2 monolayers.17 Further work showed that PAMAM dendrimer 




indicates that endocytic mechanisms are involved in dendrimer transport, these 
studies also showed that dendrimers facilitated tight junction opening, as 
evidenced by occludin staining and increased mannitol transport.10,13,14,28,29 Thus 
the route of dendrimer penetration across Caco-2 monolayers appears to be via 
a combination of the transcellular and paracellular route. Alternative data 
achieved in CD-1 mice indicated no increase in mannitol permeability or tight 
junction opening when PAMAM dendrimers were administered orally at 
concentrations greater than those used in Caco-2 cell cultures (e.g., G4-NH2 
(2.1mM), G3.5-COOH (7.7mM)).21 This apparent discrepancy may be due to the 
differences between the models used. Cell culture models lack some of the 
properties that native tissues contain. In comparison to in vivo models, Caco-2 
cell monolayers lack mucus layers, extracellular matrix proteins, supportive 
mixed cell populations, basement membranes and metabolic protein expression. 
Indeed, Caco-2 cell cultures can give a wide range of transport data based on 
differences between source,30,31 selection pressure,30 passage number,32 and 
tissue culture conditions.33–35 Caco-2 cells have been noted for their increased 
sensitivity to penetration enhancers, excessively high resistant tight junctions and 
increased indications of cytotoxicity upon exposure to enhancers compared to 
native isolated rat and pig intestinal tissue.36,37 Thus, to account for such 
deficiencies in Caco-2 cells, we evaluated the mechanism of dendrimer 
permeability and toxicity in an isolated rat jejunal model in Ussing chambers.  
The Ussing chamber model has been used to study the mechanisms of 




utilized isolated rat intestinal epithelium to test PAMAM dendrimer transport due 
to its higher correlation to human jejunum effective permeability (Peff) than Caco-
2 cell cultures (R2=0.95 vs. R2=0.79, respectively).39 The concentration, 
incubation time, and molecular weight of dendrimers used were chosen to 
exceed typical limits of cytotoxicity in Caco-2 cultures previously observed in our 
lab, in order to see if isolated tissue histology would similarly be affected. Due to 
the hypersensitivity of Caco-2 cell cultures to penetration enhancers, we 
hypothesized that a supratoxic concentration of PAMAM dendrimers would yield 
reduced evidence of toxicity in an isolated tissue model.36,37,40 Thus, 
concentrations of 1.0 mM with an incubation time of 120 min with G4 dendrimers 
were used for this study as these have previously exhibited cytotoxicity to Caco-2 
cells (Table 3.1).10,14,15,18  
In addition the hypothesis that PAMAM dendrimers induce tight junction 
opening was explored in this study in order to reconcile results of previous mice 
and in vitro Caco-2 (Table 3.2).14,21 Concentrations, incubation times and 
generations of PAMAM dendrimers were selected that have previously been 
reported to increase mannitol permeability in Caco-2 monolayers.14 G3.5 and G4 
PAMAM dendrimers of 1.0 mM size, incubated with tissue for 90 min increased 
mannitol permeability in Caco-2.14,18 With this concentration, we planned to probe 
the differences between isolated tissue and Caco-2 models as influenced by 
PAMAM dendrimers. This study provides evidence for the role of isolated tissue 






Table 3.1. Intestinal toxicity in the presence of dendrimers* 
G3.5 PAMAM Dendrimers 
 
0.01mM 0.1mM 1mM 10mM 
90 min 
 
-a -a +a 
120 min -b -b -c-e -d 
150 min 
 




 210 min 
 
+a +a +a 
G4 PAMAM Dendrimers 
 




120 min -e-h +g +e+g -c-j +e+g 
 150 min 
  
+f +f 
180 min -i +i+k +i 
 210 min 
 
+f +f +f 
*(+) = Indication of toxicity (-) = No indication of toxicity 
a. Caco-2 - LDH release14, b. Caco-2, WST-1 assay27, c. This study - Rat 
jejunum - Histology, Carbachol Response, d. Mice, 7.7mM dose - Histology, 
TEM21, e. Caco-2 - TEM15, f. Caco-2 - LDH release13, g. Caco-2, WST-1 
assay18, h. Caco-2 - WST-1 assay17, i. Caco-2 - WST-1 Assay10, j. Mice, 





Table 3.2. Mannitol permeability in the presence of dendrimers in different 
bioassays 
G4 PAMAM Dendrimers 
  0.01mM 0.1mM 1mM 
90 min - - 8 folda 
120 min 2 foldb - 12 folda, 0 foldc,d 
G3.5 PAMAM Dendrimers 
  0.1mM 1mM 10mM 
90 min 4 folde 6 folde - 
120 min - 0 foldd 0 foldc 
a. 1:8 FITC modified18, b. Caco-210, c. 2.1mM via gavage to mice21, d. this 




Thus the aim of the studies described in this Chapter was to evaluate the 
intestinal permeability of PAMAM dendrimers G3.5 and G4 in isolated rat 
jejunum, using concentrations that probe the limits of toxicity in isolated tissue 
versus Caco-2 cell culture. Additionally, transepithelial transport of PAMAM 
dendrimers was monitored to explore the feasibility of dendrimer oral drug 
delivery for future biomedical use. 
 
3.2 Materials 
PAMAM dendrimers (G4.0 and G3.5) were purchased from Dendritech, 
Inc. (Michigan, USA). FlTC and FITC-dextran were obtained from Sigma-Aldrich 
(Dorset, UK). Acetone was obtained from VWR (Ireland). Carbachol was 
obtained from Calbiochem, Inc. (Massachusetts, USA). Disposable size 
exclusion PD-10 Columns were obtained from GE Lifesciences 
(Buckinghamshire, UK). 14C Mannitol (56.5 mCi/mmol) was obtained from Perkin-
Elmer (USA). All other reagents were obtained from Sigma-Aldrich (Ireland). 
 
3.3 Methods 
3.3.1 Synthesis of FITC-labeled PAMAM dendrimers 
FITC-dendrimer conjugates were synthesized using previous methods 
with some modifications.15 Briefly, FITC was dissolved in acetone (<5mg/mL) and 
added to amine-terminated (G4.0) dendrimers at a ratio of 1:1.2, at pH 7.4 in 
PBS. The reaction proceeded overnight with stirring at room temperature and the 




The carboxylic groups of G3.5 were activated with N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide (EDC), and then tert-butyl N-(2-
aminoethyl) carbamate (molar ratio 1:12:4) was added in PBS at a pH of 7.4. The 
reaction was then dialyzed for 24 h. The tert-butyl (Boc) protecting group was 
removed by adding 1 mL of trifluoroacetic acid to the dialysate and stirring for 4 
h, followed by further dialysis (24 h, four water changes). These slightly amine-
modified dendrimers were then reacted with FITC similar to G4.0 dendrimers 
above. 
FITC conjugated dendrimers were fractionated by size exclusion 
chromatography using a Fast Protein Liquid Chromatography (FPLC) system to 
remove small molecular weight impurities. Fractions were taken from 161mL to 
232mL elution volume. FITC conjugated dendrimers were fractionated using a 
XK 26/70 column packed with Superdex 200 prep grade media (GE Lifesciences, 
Buckinghamshire, UK) at a flow rate of 2.5mL/min of PBS (pH 7.4 PBS). They 
were then further dialyzed and lyophilized. The FITC-dendrimer conjugates were 
analyzed by FPLC to assess for small molecular weight impurities. FITC loading 
was quantified spectrophotometrically (Fig. 3.1). 
 
3.3.2 Ussing chamber experiments 
Isolated jejunal tissue was obtained from male Wistar rats (Charles River, 
UK) of weight 250-500g in accordance with the UCD Animal Research Ethics 
Committee policy on use of tissue postmortem. Rats were sacrificed by cervical 







Figure 3.1. PAMAM dendrimers were evaluated for FITC loading following 
conjugation. Samples of G3.5 and G4 FITC conjugate were weighed and then 
dissolved in 100μL PBS pH 7.4. The samples were then read for fluorescence 
(λ ex./λ em. of 495/525 nm) on a fluorescent plate reader calibrated with FITC 
standard curves on the same plate (MD Spectramax Gemini). The FITC-
loading was then quantified by calculating the concentration of FITC attached 
to the total mass of dendrimers. The molar ratio of FITC to dendrimer was 
quantified spectrophotometrically using a FITC standard curve (lower graph, 
grey line represents model fit, R2=0.98) to interpolate the FITC molar ratio of 
dendrimer-FITC conjugate (upper graph) . 





























































from cecum). Tissue was immediately immersed in fresh Krebs-Henseleit (KH) 
buffer maintained at 37°C, pH 7.4 and oxygenated with carbogen gas. Tissue 
was then opened along the mesenteric border and was pinned mucosal-side 
down on a corkboard. The external muscularis layer was then gently stripped 
away from the submucosa using a watchmaker’s size 5 fine forceps leaving an 
intact epithelium with lamina propria. Tissue was mounted between the two 
halves of an Ussing chamber (World Precision Instruments, UK) with a 5mL bath 
volume each side, a gas air-lift system and an 0.63cm2 exposed tissue area.41 
Chambers were bilaterally filled with fresh oxygenated KH buffer. Following 
mounting, mucosae were equilibrated in oxygenated buffer for 15 min followed by 
30 min of voltage clamping in order to calculate transepithelial electrical 
resistance (TEER) values and to ensure that levels were above minimum 
acceptable values (30 Ω.cm2).42 Test probes were added to apical side of tissue 
and sampling occurred (200μL) every 20 min for 120 min from the basolateral 
side, and at 0 and 120 min from the apical side. The chamber volume was 
maintained on the basolateral side by replacing sample volume with fresh 
oxygenated KH buffer after each sampling point. 
 
3.3.3 Apparent permeability (Papp) measurement 
Permeability of FITC labeled-PAMAM dendrimers (G3.5, G4.0), FITC, and 
FITC-dextran (4kDa;10 kDa) were tested across mucosae. FITC-dextrans were 
used as macromolecular control markers for paracellular flux. 0.5 μCi of 14C-




marker of paracellular permeability. Fluorescence was detected in samples using 
a spectrophotometer (λ ex./λ em. of 495/525 nm, MD Spectramax Gemini). 
Samples were then transferred to vials and mixed with 3 mL of scintillation 
cocktail (Ecoscint, National Diagnostics). Scintillation counting was performed on 
a Packard Tricarb 2900 TR (Perkin-Elmer, Ireland).  
 
3.3.4 TEER measurement 
Following permeability experiments, the electrogenic chloride secretory 
responses of mucosae were tested to ascertain retention of intestinal function. A 
cholinomimetic, carbachol, was added to the basolateral side of the chamber at 
concentrations from 0.1µM to 10µM. The change in short circuit current (∆Isc) 
was measured relative to the baseline current.43,44 Tissue was then gently 
removed and fixed in 10% buffered formaldehyde for 24 h in preparation for 
histological staining with haematoxylin and eosin (H&E) or alcian blue and 
neutral red (AB/NR).45 
The potential difference (PD) and ΔIsc across the epithelial layer was 
monitored by Ag/AgCl electrodes using an EVC-4000 amplifier (WPI, UK) and 
Pro-4 timer (WPI, UK). 3M KCl solution in 3% agar (w/v) was used as an 
electrode bathing solution. Electrical signals were converted from analogue to 
digital using Powerlab® data acquisition unit. Data were recorded with Chart® 
software (AD instruments, UK) and TEER was calculated indirectly using Ohm’s 
Law from the Isc and PD values. Voltage clamping to zero was performed using 




using the Pro-4 timer.  
Apparent permeability coefficients (Papp) of fluorescent and radioactive 
compounds were calculated using the equation:  
 
PAPP=(dQ/dt)/(Co × A) ……..…………(Equation 3.1) 
 
where dQ/dt is the rate of appearance of sample on the basolateral side, Co is 
the apical concentration and A is the exposed surface area of the tissue.  
 
3.3.5 Statistical analysis 
Permeability data were analyzed using GraphPad® Prism (version 6.0c). 
Analysis was performed using one-way analysis of variance (ANOVA) with 
Tukey’s post-test (pooled variance). Statistics on TEER values was performed 
using a two-tailed Student’s t-test comparing TEER at t=0 to the later time points. 
Values with P<0.05 were considered significant.  
 
3.4 Results 
FITC-labeled dendrimers were synthesized and fractionated to remove 
free FITC prior to testing in Ussing chambers. Purification by FPLC resulted in  
removal of small molecular weight peaks occurring after 232 mL elution volume 
on the XK 26/70 column (Figure 3.2).  
Papp values for FITC-labeled PAMAM dendrimers through isolated rat 








Figure 3.2. Size exclusion chromatograms of G3.5-FITC and G4-FITC 
conjugates before and after fractionation. Grey line = before fractionation, 





































G4.0 dendrimers was not statistically increased compared to free FITC, although 
there was a trend. Importantly, the Papp of FITC-dextran (both 4kDa and 10 kDa) 
was not different from that of free FITC (Figure 3.3), so it is not the case that 
conjugation to any molecule increases the FITC Papp per se. The [14C]-mannitol 
Papp was not significantly increased in the presence of either of the two dendrimer 
conjugates compared to untreated (Figure 3.4). 
The average basal TEER for jejunal segments was 57±20 Ω.cm2 (n=45). 
This is consistent with previously reported rat jejunal TEER values.40,44,46 TEER 
values of the control, G4.0 dendrimer and FITC dextran treatments were 
significantly reduced after 40 to 60 min in Ussing chambers compared to 
baseline TEER at t=0. The TEER of the G3.5 treatment was observed to drop 
much more rapidly, reaching significantly reduced levels at t=5 min and onward 
(P<0.05). Decreases in TEER were not reflected in increased Papp of mannitol 
(Figure 3.4), so the relevance of transient TEER decreases to overall paracellular 
permeability is questionable (Figure 3.5). 
The electrogenic chloride transport secretory response to carbachol 
showed similar concentration-dependent, large ISC increases in jejunal mucosae 
exposed to apical additions of both unconjugated dendrimers and FITC dextrans 
for 120 min (Figure 3.6). Carbachol-stimulated ISC increases in the presence of 
dendrimers were similar to untreated controls and demonstrated that tissue 
secretory function was retained.  
Histological evaluation at 120 min postmounting in chambers showed mild 






Figure 3.3. Papp of FITC-PAMAM (1.0mM), FITC-dextran 4kDa (0.625mM), 
FITC-dextran 10kDa (0.25mM) and free FITC (0.02mM) across isolated rat 
jejunum. FITC-G3.5 dendrimers had significantly increased Papp compared to 



























































Figure 3.4. Papp of [14C]-mannitol through isolated rat jejunum. No significant 
difference was observed for G4.0 and G3.5 dendrimer (1.0mM) treatments 
versus free FITC, indicating no enhanced paracellular transport in the 









































Figure 3.5. Percent TEER changes of isolated jejunal tissue. Control ( ), G4 
dendrimers 1.0mM ( ), G3.5 dendrimers 1.0mM ( ), FITC-dextran 4kDa (Δ), 
FITC-dextran 10kDa (). Percent TEER values were calculated as a 
percentage of the initial TEER at t=0 in each group. Significant differences 
from TEER of each individual group at t=0 are marked with open circles (G3.5 
dendrimers), star (control, G3.5 dendrimers, FITC-dextran 4kDa), and asterisk 
(all groups). 





























Figure 3.6. ΔISC response to basolateral additions of carbachol to jejunal 
mucosae. No significant difference in response was observed for test groups. 
-




dendrimers was significantly increased over that of free FITC. The Papp of FITC-
lymphatic drainage, but there was no significant membrane disruption due to 
dendrimer treatments (Figure 3.7). All tissues therefore showed an intact barrier, 
consistent with the retention of secretory ion transport capacity. 
The absence of small molecular weight FITC of the FITC-dendrimer 
conjugate was monitored through size exclusion chromatography on PD-10 
columns after each experiment. FITC-dendrimers collected from the basolateral 
chamber remained stable, with no appearance of the free label peak (30mL 
elution volume) compared to the dendrimer peak (6mL elution volume). This 
signifies that detected fluorescence on the basolateral side of the chamber was 
not due to free FITC cleaved from the dendrimer, but rather due to the FITC-
labeled dendrimer. This result is critical to validating the stability of the conjugate 
during the 120 min flux period (Figure 3.8). 
 
3.5 Discussion 
PAMAM dendrimers have shown the capacity to permeate the small 
intestinal epithelium, and to increase the solubility of co-presented drugs in vitro 
and in vivo.2 Their size and surface functionality makes them capable of a variety 
of biomedical functions.3 The potential for PAMAM dendrimers in oral drug 
delivery has been validated in cell culture models and in animals.9,11–14,21 It is 
remarkable that selected PAMAM dendrimers penetrate the rat small intestinal 
epithelium in spite of their large molecular weight, complex macromolecular 





Figure 3.7. H&E staining of isolated jejunal tissue after 120 min incubation in 
Ussing chambers. No difference in histology was observed between controls 
and dendrimer-treated tissue. 1mM G3.5 dendrimer (upper), 1mM G4 





Figure 3.8 The absence of free FITC during the Ussing chamber studies was 
evaluated by use of size exclusion chromatography on PD-10 columns after 
each experiment. Basolateral solutions were removed after the experiment 
and stored in 4°C until running on PD-10 columns. Each column was used one 
time to test for small molecular weight free FITC. Columns were washed prior 
to use with 12mL of PBS pH 7.4. 500μL of the basolateral solution was loaded 
onto the column followed by 1.5mL PBS. The eluted void fraction was 
collected (2mL) followed by 4mL fractions thereafter. Samples were collected 
into spectrophotometer cuvettes and analyzed for absorbance at 495nm 
(Pharmacia Biotech, Ultraspec 200 UV/Vis), as fluorescence signal was too 
weak to detect following dilution on the column. Blank elution solvent (PBS pH 
7.4) was used to zero the absorption signal prior to each sample analysis and 
after each analysis to affirm that there was no drift in absorption signal. 
Stability of the FITC-dendrimer conjugates was monitored by size exclusion 
chromatography (PD-10) following fluxes across jejunal mucosae. FITC 
labeled dendrimers showed no peaks corresponding with free FITC at 120 min 
as detected by absorbance at 495nm (Free FITC – blue, G4 dendrimers – red, 
G3.5 dendrimers – green). 

















permeated the rat jejunum very well compared to free FITC, as indicated by a   
Papp in excess of 7x10-6 cm/s. Although the probes would still be classified into 
BCS class III for low permeability/ high solubility molecules based on the results 
of this study, such a Papp value is associated with an in vivo human fad of 40-
60%.47 Indeed, anionic G6.5 PAMAM dendrimers that have a molecular weight 8 
fold larger than the probes in this study have been observed to have an fa of 
9.4% in mice.11 Since larger molecules are generally more slowly absorbed than 
smaller ones, it is reasonable to expect an fa of 40-60% for the lower generation 
dendrimers studied here, but this could be argued based on the lower number of 
functional groups interacting with tissues in small generations. Future clinical 
application of PAMAM dendrimers rests upon careful evaluation of these 
parameters. The permeability of G3.5 and G4 dendrimers in Caco-2 cells has 
been previously studied in Caco-2 cell cultures and isolated tissue, facilitating 
comparison of results obtained from isolated tissue and cell culture models.10,16,18 
Kolhatkar et al. observed G4 dendrimers with a Papp 1.5×10-6 cm/s in Caco-2 
cultures at 120 min incubation time.10 This value of Papp was much less than the 
value of Papp  (4.47×10-6 cm/s) we observed in this study, but the apical 
concentration was also 100 fold less. Kitchens et al. observed a Papp value for G4 
dendrimers ranging from 20-35×10-6 cm/s at 1.0mM for 60-120 min incubation  
times.18 These results far exceed the values obtained in our study, but the 
dendrimers used in their study had a ratio of dendrimer to FITC of 1:8, potentially 
altering the physiochemical properties (the dendrimers in this study had a 




G3.5 PAMAM dendrimer Papp values in previous studies were less variable 
in comparison (Table 3.1). Results from multiple Caco-2 studies observed Papp 
values ranging from 2.5×10-6 cm/s at 0.1mM to 6×10-6 cm/s at 1mM and 120 min 
timepoints.16,18 The values of Papp for G3.5 dendrimers obtained in this study 
were in the same range as previous results from Caco-2. These results add to 
the debate on whether hydrophilic macromolecules and nanoparticles can 
penetrate the intestinal epithelium.48,49 Similar molecular weight dextran 
molecules (4 and 10kDa) did not cross the intestinal barrier to the same extent as 
the G3.5 (12.9kDa) and G4 (14kDa) dendrimers, indicating the unique 
physiochemical characteristics and structure of dendrimers facilitate their higher 
than expected transepithelial transport.12  
In an initial study Wiwattanapatapee et al. evaluated the transepithelial 
transport of G4 and G3.5 PAMAM dendrimers in everted rat intestinal sacs.19 
This study compared the endocytic index (EI) of the dendrimers (ng dendrimer 
transferred/mg intestinal tissue protein), bovine serum albumin (BSA) and other 
polymers. G3.5 and G4 dendrimers were noted for their higher EI than BSA and 
poly(vinyl pyrrolidone) polymers. Comparison to this study is not facilitated by the 
nature of the permeability data obtained (EI vs. Papp). Although the permeability 
data in that study were not entirely linear, this study indicated that PAMAM 
dendrimers penetrate the intestinal epithelium.19 
The secondary aim of this study was to compare mechanistic information 
obtained from mannitol permeability in this study to previous results obtained in 




were exposed to 1mM G3.5 and G4 PAMAM dendrimers. These results are in 
contrast to previous studies in Caco-2 where increased transport of mannitol in 
the presence of 1.0 mM G3.5 and G4 dendrimers was observed. G3.5 
dendrimers at 120 min were observed to increase mannitol Papp 6 fold, while G4 
dendrimers at 120 min incubation time showed a 12 fold increase (Table 3.2).14 
This discrepancy may be due to the differences between isolated tissue models 
and Caco-2 cell culture. Isolated rat jejunal mucosae contain properties that map 
to the human jejunum.39 These include mucus layers, extracellular matrix 
proteins, host enzyme levels,47 supportive cells and basement muscle layers.50–52 
Lacking mucus and supportive cells underlying the epithelial barrier, Caco-2 cell 
cultures may be sensitive to PAMAM dendrimer induced mannitol permeability 
enhancement compared to rat jejunal mucosae. Other studies have noted the 
increased sensitivity of Caco-2 cells to penetration enhancers, compared to 
isolated tissue.36,37 A recent study in CD-1 mice orally gavaged with G3.5 or G4 
dendrimers formulated with [14C]-mannitol also showed no induction of 
paracellular transport of mannitol confirming the results of this study.21 Since 
mannitol is an indicator of tight junction opening and enhanced paracellular 
transport, this suggests that PAMAM dendrimers do not increase paracellular 
transport in isolated tissue and oral gavage in vivo, at the concentrations, 
generations, surface modifications and incubation times studied.  
The alternative possibility would be transcellular route via an endocytic 
pathway. In parallel with the tight junction route, it has been confirmed in Caco-2 




endocytic inhibitors.17 Further work showed a decrease in G3.5 PAMAM Papp 
during incubation with clathrin inhibitor (mondansyl cadaverine) or dynamin 
inhibitor (dynasore). The caveolin inhibitor, genistein, did not have a significant 
effect, indicating that transport across the membrane may depend primarily on 
clathrin-mediated transcytosis.28 The effect of PAMAM dendrimers on the viability 
of epithelial layers was compared to controls. G3.5 and G4 PAMAM dendrimers 
of 1.0 mM concentration retained functional electrogenic chloride secretory 
pathways after 120 min incubation, indicating a lack of apical membrane 
disruption. Also, histological evaluation of the tissue showed intact villous 
structure. The signs of toxicity differ significantly in comparison with Caco-2 cell 
culture studies. In Caco-2 studies significant toxicity was observed at 
concentrations >0.1 mM and >90 min incubation times for G4 PAMAM 
dendrimers13,15,18 and >1 mM and >150 min incubation times for G3.5 
dendrimers, respectively.14 Indications of reduced proliferation,10,17,18,28 
mitochondrial damage,29 and cellular membrane damage13,14 have been 
apparent. These effects were dependent on concentration, incubation time and 
assay as reviewed in Table 3.1. Suffice to say that the results of this study 
concord with in vivo studies performed in CD-1 mice that showed no toxicity for 
both PAMAM generations by TEM, morphological evaluation of microvilli as well 
as histological evaluation of intestinal epithelium.21 The concentrations used in 
the in vivo study were actually higher than those in the present one. Similar oral 
studies have shown no signs of toxicity in CD-1 mice when dosed at 300mg/kg 




understand the upper limit of safe oral PAMAM dendrimer administration. These 
studies give rationale for the potential use of PAMAM dendrimers to carry poorly 
bioavailable drugs across the intestine to their site of action. Future clinical 
application of PAMAM dendrimers rests upon careful evaluation of their 
permeability and toxicity profile.  
 
3.6 Conclusion 
The elevated transport of the G3.5 PAMAM dendrimers through isolated 
tissue gives rationale for dendrimer usage in oral drug delivery. The high 
permeability may indicate that PAMAM dendrimers can carry payloads into 
systemic circulation (such as poorly permeable and poorly soluble drugs (BCS 
Class IV)). PAMAM dendrimers’ transport through isolated intestinal epithelia 
was greater than controls and greater than similar size FITC-labeled dextrans. 
Our results show minimal indication of toxicity to the epithelial barrier when 
treated with PAMAM dendrimers at concentrations of 1.0mM. This provides 
evidence that PAMAM dendrimers may be able to be dosed at nontoxic 
concentrations, yet still penetrate to a sufficient extent for increasing drug 
absorption. Payloads could potentially be delivered as a mixture or as conjugated 
moiety. Future work should be aimed at further understanding of the 
physiochemical characteristics that promote increased transepithelial transport 
and specific therapies for oral drug delivery. Results of this study indicate the 
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REGIONAL MORPHOLOGICAL DIFFERENCES AND TRANSPORT  
OF PAMAM DENDRIMERS ACROSS ISOLATED  




Polymeric drug delivery has had a significant impact on clinical medicine, 
specifically by increasing drug circulation half-life, enhancing water solubility and 
reducing nonspecific uptake of drugs by nontarget organs.1 With two polymeric 
drugs (Pegfilgrastim and Glatiramer acetate) amongst the 10 top selling drugs in 
the U.S. for 2014, the potential for polymeric systems to benefit the landscape of 
clinical biomedicine is tremendous.2  
Polymeric systems have limited oral bioavailability.3,4 Oral drug delivery is 
preferable over intravenous injections due to the ease of treatment, reduction in 
medical personnel required to administer the drug and reduction in patient time in 
hospitals. Additional factors that make oral delivery preferable include the 
reduced risk of needle borne infections and the improved pharmacokinetic profile 
of oral drugs versus bolus intravenous injections.5 These aspects provide 




Poly(amido amine) (PAMAM) dendrimers are a class of hyperbranched 
polymers with nanoscale dimensions and potential clinical application in oral drug 
delivery.4,6 Dendrimers have multiple surface functional groups making them 
ideal for attachment of imaging agents, targeting ligands and therapeutic 
moieties.7–12 Hydrophilic dendrimers can improve solubility of poorly soluble 
drugs.13 PAMAM dendrimers have been observed to traverse the Caco-2 cell 
monolayers and enhance the permeability of drugs.14–16 Kitchens et al. observed 
that generation 4 (G4) PAMAM dendrimers had a Papp in excess of 15×10-6 
cm/s in Caco-2 cell monolayers.15 D’Emanuele et al. observed that G3 PAMAM 
dendrimers could enhance the transepithelial transport of propanolol across 
Caco-2 cell monolayers and significantly reduce its efflux by P-gp transporters.17 
The mechanism of dendrimer transport appears to be via a dynamin-dependent 
endocytosis and enhancement of paracellular permeation across epithelial 
barriers.18,19 Specific CaMPKII inhibitors (KN62) have been observed to decrease 
dendrimer-induced tight junction opening (as reflected by increased [14C]-
mannitol Papp) in the presence of G3.5 dendrimers, thus implicating the CaMPKII 
molecular mechanism in dendrimer penetration in Caco-2 monolayers.19 Other 
studies have noted the ability of PAMAM dendrimers to form perforations in 
plasma membranes (5-40nm in size), giving rationale for their interactions with 
lipidic membranes.20 These mechanistic studies implicate dendrimers as having 
a specific charge-dependent effect on epithelial barriers that enables them to 
penetrate the intestinal epithelium by both paracellular and transcellular routes. 
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Significant in vivo evidence exists for the potential of PAMAM dendrimers 
to permeate intestinal tissue.21 G6.5 PAMAM dendrimers have shown an oral 
fraction absorbed of 9.4% in mice.22 In vitro studies with everted rat intestinal 
sacs have noted an endocytotic index for PAMAM dendrimers, which was higher 
than that of bovine albumin, N-(2-hydroxypropyl)methacrylamide, and N-
vinylpyrrolidone-co-maleic anhydride.23 Studies in our lab have noted the 
capacity of PAMAM dendrimers to increase the absorption of drugs both mixed 
with, or covalently attached to the dendrimer in vivo and in vitro.6,24 Further 
investigations with rat isolated jejunal mucosae noted the higher Papp of G3.5-
fluorescein isothiocyanate (FITC) labeled dendrimers compared to free FITC.25 
This body of evidence gives rationale for the development of PAMAM dendrimers 
as oral drug delivery carriers, since they appear to be both transported across 
epithelial barriers and to enable absorption of associated pay-loads. 
PAMAM dendrimers may have therapeutic potential, but the toxic 
interaction with the intestinal epithelium has also been noted.3 Previous work in 
Caco-2 cell monolayers and intestinal tissues showed that positively-charged 
dendrimers disrupted cell membranes (as indicated by lactate dehydrogenase 
(LDH) release and morphological damage) compared to neutral- or negatively- 
charged dendrimers.14,15,25–27 The cellular damage observed was incubation 
time- and concentration dependent.14,26 LDH was released following exposure to 
0.1mM G4 or G3.5 dendrimers in Caco-2 monolayers for 210 min.14,26 Higher 
concentrations of G3.5 and G4 induced LDH release at earlier time points, 150 
min and 90 min. On the other hand, oral dosing studies performed in CD-1 mice 
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dosed at 1000mg/kg PAMAM G3.5 dendrimers (~7mM intestinal lumen 
concentration) showed no intestinal morphology damage.6 Consistent with that, 
no significant signs of histopathology were observed in isolated rat jejunal 
mucosae after 120 min incubation with 1 mM G3.5 and G4.25 This trend led us to 
conclude that Caco-2 cell monolayers appear to be more sensitive to dendrimer -
induced permeation enhancement and damage than isolated tissue or in vivo 
rodent models. Indeed, increased sensitivity of Caco-2 monolayers to penetration 
enhancers has been observed previously.28,29 The discrepancy between the toxic 
concentration in cell culture and animal models has led us to re-evaluate the 
potential adverse effects of PAMAM dendrimers in isolated tissue models using 
Ussing chamber in order to help establish safe dose levels for PAMAM 
dendrimer oral drug delivery. 
In addition to the maximum tolerated concentration of dendrimers by 
tissue mucosae, this study also sought to assess the regional transport of 
PAMAM dendrimers in rat colonic and jejunal mucosae, and to compare 
permeability Papp values between Caco-2 and isolated mucosae. Previously, we 
established the Papp of G3.5 and G4 across rat jejunal mucosae, but the colonic 
transport was not carried out.25 Many penetration enhancers have significantly 
increased effects in colonic epithelium compared to jejunal tissues.30 For this 
purpose we also explored the Papp of G3.5 and G4 in colonic mucosae to assess 






Fluorescein isothiocyanate (FITC) (cat. no. F7250), fluorescein 
isothiocyanate dextrans (cat. no. FD10S) and N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide (EDC) were obtained from Sigma-Aldrich. PAMAM dendrimers 
(G3.5-COOH and G4.0-NH2) were obtained from Dendritech Inc. (Michigan, 
USA). 14C mannitol (0.1mCi/mL in sterile water) was obtained from American 
Radiolabeled Chemicals (Missouri, USA). Gases were obtained from AirGas 
Corp (UT, USA). Cells were purchased from American Type Culture Collection 
(Rockville, MD). All other reagents were obtained from VWR.  
 
4.3 Methods 
4.3.1 Synthesis of FITC-labeled PAMAM dendrimers 
FITC labeled conjugates were prepared as reported previously.15,25 Briefly 
G3.5 dendrimers were dried from methanolic solution and dissolved in PBS pH 
7.4. Ethylenediamine (ED) was conjugated to G3.5 dendrimers using a feed ratio 
of 1:4 dendrimer to ED. EDC was added to G3.5 dendrimers in PBS at 0°C for 
the first 30 min followed by the addition of ED. The reaction was allowed to stir 
overnight, followed by the addition of FITC at a feed ratio of 1:1.2, PAMAM 
dendrimer to FITC to complete the conjugation. G4 PAMAM dendrimers were 
mixed with FITC at a similar feed ratio in PBS to conjugate the FITC. All 
conjugates were then dialyzed for 48 h against deionized (DI) water. The final 
product was purified via fast protein liquid chromatography (GE life sciences) 
using an XK 26/70 column packed with Superdex 30 media at a flow rate of 
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2.5mL/min using PBS pH 7.4 as the eluent. The final purified compounds were 
dialyzed against DI water and lyophilized. The conjugates were characterized for 
absence of free FITC using Superose 6 column at a flow rate of 1 mL/min. FITC 
loading was assessed by spectrophotometry (Figure 4.1 and 4.2).  
 
4.3.2 Caco-2 monolayer permeability 
Caco-2 cell cultures were prepared according to previously published 
methods.31 In brief, cells (passage 6-16) were grown at 37°C under a 5% CO2 
atmosphere in air with 95% relative humidity using Dulbecco’s Modified Eagles’s 
Medium with 10% fetal bovine serum (FBS). The media was changed every two 
days until 90% confluence was attained. Cells were passaged at least twice 
using trypsin-like enzyme (Gibcolife, NY, USA) before seeding onto Transwells®. 
Cells were seeded on 24-well polyester Transwells® (Sigma Aldrich, cat. no. 
CLfigure470-48EA) at a density of 2.6×106 cells/cm2 and grew for 21-29 days 
before use. Transport medium consisted of Hank’s balanced salt solution (HBSS) 
supplemented with 10 mM N-(2-hydroxyethyl)piperazine-N´-Poly(Amidoamine) 
(2-ethanesulfonic acid) hemisodium salt (HEPES) buffer (pH 7.4).  
 Transport experiments were carried out with 60 min of incubation with 
transport medium, prior to treatments. At t=0 min, the transport buffer was 
decanted and treatment was added to the apical side. FITC-G3.5 and G4 
dendrimers were added at 0.1mM concentrations in the transport buffer. 
Monolayers were then incubated at 37°C on an orbital shaker at 350 RPM (G76, 




Figure 4.1. 14C mannitol permeability across Caco-2 cells in the presence of 
dendrimers (top panel) and permeability of FITC-labeled dendrimers across 
Caco-2 cells (bottom panel). The permeability of fluorescently labeled G3.5 
dendrimers trended higher than free FITC (a small molecular weight control), 
while the permeability of G4 dendrimers was similar to free FITC. 4kDa FITC-
labeled dextrans (FD4) were tested to compare to another inert 
macromolecule. FD4 had a permeability that trended lower than dendrimers 
and controls. Mannitol permeability showed no significant change compared to 






























































































Figure 4.2. Dendrimer effect on percent transepithelial electrical resistance (% 
TEER) values in isolated rat intestinal tissue. Top panel: colon. Bottom panel: 
jejunum. PAMAM dendrimers had a concentration dependent effect on rat 
jejunal and colonic TEER. 0.1 mM concentration of dendrimers did not reduce 
TEER compared to control in colonic and jejunal tissue. 1.0 mM G3.5 
dendrimers had a statistically significant reducing effect on TEER in both 
colonic and jejunal epithelium, while 1.0 mM G4 dendrimers had no such 
effect. 10 mM concentration of dendrimers immediately caused a reduction in 
TEER which lasted for the duration of the experiment in both types of tissues 
(n=3-12). * signifies p<0.05 compared to control. 
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the basolateral side starting at t=0 for 120 min and the volume was replaced by 
warm oxygenated buffer. Fluorescent samples were quantified using an 
excitation wavelength of 495 and emission wavelength of 525 on 
spectrophotometer (Spectramax M2, Molecular devices, CA, USA). All 
experiments included 5 µL of 14C-mannitol as an internal control, which was 
quantified using liquid scintillation (LS-6000IC, Beckman, CA, USA). 
 
4.3.3 Ussing chambers 
Animals were used according to the University of Utah Institutional Animal 
Care and Use Committee (IACUC) and the American Board of Veterinary 
Medicine guidelines. Female SAS-Sprague- Dawley rats were obtained from 
Charles River Labs (NY, USA) and housed in animal facilities on a 12-h light dark 
cycle with food and water ad libitum. Rats were used with a body weight range of 
224-300 grams. Animals were euthanized via CO2 asphyxiation followed by 
immediate dissection and removal of jejunum (approximately 20cm proximal to 
the cecum) or colon (approximately 2-3cm distal to the cecum).32,33 Tissue was 
immediately immersed in ice cold oxygenated Krebs-Hensleit (KH) buffer at pH 
7.4 and all further dissection was performed in a custom-designed oxygenated 
tissue dissection bath. Tissue was opened along the mesenteric border and 
pinned apical side down inside the mounting bath. The external muscularis layer 
was removed using No. 5 forceps and the intact epithelium was mounted in Easy 
Mount Ussing chambers with P2304 inserts (Physiologic Instruments, CA, USA) 
with a surface area of 0.3 cm2. Chambers were filled with 5mL Krebs-Hensleit 
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buffer gassed with 95% O2/5% CO2 and equilibrated for 45 min at 37°C prior to 
treatments. 
At time t=0 min, solutions containing FITC- or unlabeled dendrimers were 
added to the apical side of tissue. Dendrimers were added at concentrations of 
0.1, 1.0, or 10mM for non-labeled and at 1.0mM concentrations for FITC labeled. 
All experiments included 5µL of 14C-mannitol as an internal control. The apical 
and basolateral side of the chambers were sampled at t=0 min and volume was 
replaced with 37°C, oxygenated KH buffer to maintain the volume at 5mL. The 
apical side was sampled at t=0 and 120 min while the basolateral side was 
sampled at t=0 min followed by 20 min intervals for 120 min. Samples were 
quantified as above. 
The apparent permeability coefficients (Papp) of radioactive and fluorescent 
compounds was calculated using the equation:  
 
PAPP=(dQ/dt)/(Co × A)………………...(Equation 4.1) 
 
where dQ/dt is the rate of appearance of sample on the basolateral side, Co is 
the apical concentration and A is the exposed surface area of the tissue. Linear 
rates of permeability with an R2 value above 0.75 were used for calculating 
permeability. Statistical analysis of the Papp data was compared using ANOVA, 





4.3.4 Transepithelial electrical resistance 
TEER was measured using an EVOM-2 TEER measurement device 
(Warner Instruments, Sarasota, FL, USA) attached to AgCl electrodes 
(Physiologic Instruments, CA, USA) immersed in 3% agar and 3M KCl. TEER 
measurements were taken 15, 10 and 0 min before treatment and every 5 min 
thereafter for the initial 20 min. Following this, TEER was measured every 20 min 
for an additional 2 h. Statistical analysis of TEER results was performed using 
Student’s t-test compared to the control values. After the completion of the 
experiment, the tissue was removed from the chambers and fixed in 10% neutral 
buffered formalin for 48 h followed by storage in 70% ethanol in water. Tissues 
were mounted in paraffin blocks and stained using hematotoxilin and eosin 
(H&E) for morphological evaluation of epithelial tissue.34 
 
4.4 Results 
Caco-2 monolayers had FITC-dendrimer and 14C mannitol Papp values 
comparable to previously reported results.14,15 The permeability of FITC-
dendrimers was not significantly higher than the FITC control or 4kDa FITC 
dextran. Permeability results were not due to the free label as confirmed 
previously by size exclusion chromatography.25 All permeability values were less 
than the positive control of Triton®-X-100 (Figure 4.1). 
Regional differences in fluorescent PAMAM dendrimer transport were 
observed in isolated rat intestine. FITC-G4 and FITC-G3.5 Papp values were 
significantly increased in jejunal mucosae compared to colonic. G3.5-FITC-
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dendrimer transport in jejunal mucosae was greater than the respective free 
FITC controls in jejunum and colon tissue (p<0.01). On the other hand, jejunal 
transport of G4-FITC was not greater than FITC controls in jejunum. In colonic 
tissue, G3.5 and G4 transport was no greater than free FITC indicating that 
PAMAM dendrimer transport was greatly enhanced at the same concentration in 
jejunum. Differences in absorptive microvilli surface area between jejunal and 
colonic epithelium may be the cause of the different Papp values even in windows 
of the same area.35  
Unlabeled PAMAM dendrimers (G3.5 and G4) were observed to have 
differing effects on rat intestinal TEER. G3.5 and G4 dendrimers both reduced 
TEER with increasing concentration. The concentration at which TEER reduction 
was reduced was dependent on the charge of the dendrimer. 1 mM G3.5 
dendrimers caused a significant decrease in TEER in jejunum between 10-40 
min. time points, but returned to a non-statistically significant reduction at later 
time points (p<0.05). G4 dendrimers had no significant TEER reduction at 
concentrations of 1.0 mM in jejunum. A significant decrease in TEER at 10mM 
concentrations in rat jejunal tissue was observed for G3.5 and G4 dendrimers. 
G3.5 and G4 dendrimers at 0.1mM concentrations had no significant effects on 
jejunal TEER. 
In colonic tissue the TEER values were significantly reduced by G3.5 (1 
mM), while G4 dendrimers had no effect. At 10mM, both G4 and G3.5 
dendrimers caused a significant reduction in TEER after 5 min (p<0.05). The 
TEER reduction was greater for G3.5 dendrimers than G4 (both 10mM), whereas 
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0.1 mM G3.5 and G4 caused no change. 
14C mannitol basal Papp values were consistent with previous literature 
reports for isolated rat intestinal epithelium.30,32,36,37 An increasing trend in 
permeability was correlated with an increased unlabeled dendrimer concentration 
in isolated rat jejunum (Figure 4.3). This trend in mannitol permeability 
enhancement was similar for G4 and G3.5 dendrimers, although neither was 
significantly different from control (p<0.05). This trend is consistent with the 
inverse relationship of mannitol permeability and TEER values observed in prior 
experiments.31 
Tissue morphology in isolated rat jejunum was only affected by unlabeled 
dendrimer concentrations in excess of 1 mM. In general, all tissues (including 
controls) in Ussing chambers displayed minor sloughing of epithelia, and edema 
due to the lack of lymphatic drainage (typical of isolated tissue models). Jejunal 
mucosae treated with G3.5 and G4 dendrimers at 0.1mM and 1.0mM 
concentrations showed no major structural difference from control. Ten mM G3.5 
dendrimers caused a significant reduction in the tissue thickness along the crypt-
villus axis and significant sloughing off of epithelial cells (Figure 4.4).  
Colonic epithelial tissues were observed to have sloughing of surface cells 
at concentrations as low as 0.1mM for G3.5 dendrimers. G4 did not exhibit any 
significant sloughing of epithelial layers until 10mM concentrations were used. 
These data correspond with TEER and mannitol permeability, which are not 
affected by G4 at 0.1 and 1 mM concentrations, but are mildly affected by G3.5 




Figure 4.3. 14C mannitol permeability in isolated rat intestinal tissues. Top 
panel: colon, bottom panel: jejunum. 14C mannitol permeability was observed 
to have an increased trend in colonic epithelium when exposed to increasing 
concentrations of G3.5 dendrimers for 120 min. Although no concentration 
caused a significant increase in mannitol, the 10 mM concentrations had the 
greatest positive effect on mannitol permeability. G4 dendrimers had a similar 
effect on jejunal epithelium, with a trending increase in mannitol permeability. 
The effect of G4 dendrimers on mannitol permeability enhancement appeared 
lower in colon tissues than jejunal epithelium. The control treatment is in the 



























































































































Figure 4.4. H&E evaluation of isolated rat jejunal epithelial tissue treated with 
G3.5 and G4 dendrimers for 120 min. G3.5 and G4 dendrimer treatment had 
no significant effect up to 1.0mM concentrations. 10mM concentrations of 
G3.5 and G4 caused significant reduction of tissue width along the crypt-villus 
axis (top to bottom) as well as major sloughing of epithelial layers. Panels are 
arranged in the following order: control (A, E), G3.5 0.1mM (B), G3.5 1.0mM 





Figure 4.5. H&E evaluation of isolated rat colonic epithelial tissue treated with 
G3.5 and G4 dendrimers for 120 min. G3.5 treatments were observed to 
cause significant sloughing of epithelial cells at concentrations as low as 
0.1mM (B, C & D). G4 dendrimers did not seem to have a serious effect on 
colonic morphology until 10mM concentrations were reached, where the 
epithelial surface was disrupted. This is consistent with TEER and mannitol 
data showing reduced effects in colonic epithelium. Panels are arranged in the 
following order: control (A, E), G3.5 0.1mM (B), G3.5 1.0mM (C), G3.5 10mM 




















































































































































































































































































































































PAMAM dendrimers have been observed to traverse the intestinal 
epithelium in vitro and in vivo indicating that they may be useful for oral drug 
delivery of associated molecules. The rate of their intestinal transport was first 
reported by Wiwattanapatapee et al. across everted sacs.23 Since then, a variety 
of studies have shown the capacity of PAMAM dendrimers to enhance 
permeability.3,8 In the studies described in this Chapter we observed that PAMAM 
dendrimers were capable of traversing the rat intestinal membrane to a greater 
extent in jejunal than colonic epithelium. This difference in transport may be due 
to the greater absorptive surface area of small intestine, compared to colonic 
epithelium, even in Ussing chambers (6/1 ratio in rat).35 In addition, the colon of 
rats has a mucous layer of approximately 830 µm thick compared to the jejunum 
mucous thickness of approximately 123 µm.38 Mucous layer thickness may cause 
differing degrees of entrapment, especially for cationic dendrimers, which are 
likely to interact with the anionic mucous layer and restrict access to the 
epithelium.39 
TEER values for colon and jejunal epithelium treated at equal 
concentrations (1mM) of FITC or non-FITC G3.5 and G4 were statistically 
reduced only by the G3.5 treatment. This may be an effect of mucous 
entrapment of cationic G4 dendrimers as well. This mucus-protective effect may 
reduce the interaction of G4 dendrimers with epithelial layers, while anionic 
dendrimers penetrate the mucous layer and begin to reduce the TEER of the 
epithelial cells at a much lower threshold. At 10mM, both G4 and G3.5 have  
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similar TEER-reducing effects on colon and jejunum, likely due to the high 
concentration of dendrimer, which would inhibit any observable effect of mucous 
entrapment on TEER. Future experiments may be aimed at discovering the 
extent of mucus-entrapment for cationic dendrimers and the difference that 
charge has on this entrapment. 
It appears that a similar trend is observed in colonic histology, where G3.5 
dendrimers caused sloughing of epithelial layers, at much lower concentrations 
than G4 dendrimers. At 1.0mM exposure colon morphology was significantly 
affected by G3.5 treatment, whereas the epithelial surface was mostly intact for 
G4 treatments at the same concentration. This provides evidence that G3.5 
dendrimers might cause damage to epithelial layers at low concentrations, 
whereas higher concentrations of G4 dendrimers are needed for such impact. 
In jejunal mucosae, the tissue morphology was intact when exposed up to 
1mM G3.5 and G4 dendrimer. Ten mM caused a significant decrease in TEER 
and a loss of epithelial layers in all tissue types and with all dendrimer 
generations tested. This concentration also caused a trending increase in 
mannitol permeability in the small and large intestinal epithelium. This is 
indicative of a potential upper safety limit for PAMAM dendrimer oral drug 
delivery. It is interesting to note that this upper limit is 10-100 fold higher in 
concentration than suggested by previous work in the Caco-2 model.14,26 This 
result, while not surprising, confirms differences in sensitivity between isolated 
tissue models and cell culture. 
Of significant note was the comparison of Papp values in intestinal tissue 
136 
 
compared to the Caco-2 models (Figure 4.6). The Caco-2 Papp of G3.5 and G4 
dendrimers was similar to that of rat jejunal mucosae. In spite of the Caco-2 cell 
line being derived from colonic epithelium, the permeability values observed were 
found to overestimate colonic epithelial transport. Permeability values obtained in 
Caco-2 models (especially for passively accumulated drugs) have been found to 
closely match jejunal transport in human tissues.40  
While the concentration of dendrimers appears to have an impact on 
epithelial morphology, TEER and paracellular permeability, the actual 
concentration in vivo may be significantly altered by dilution, mixing, reserve time 
and degradation inside the gastrointestinal tract. G3.5 dendrimers appear to have 
greater effect on epithelial TEER and morphology at lower concentrations while 
G4 dendrimers appear to show observable damage to epithelial layers at higher 
concentrations (>10mM).  
 
4.6 Conclusion 
In this chapter we sought to investigate the regional dependence of 
PAMAM dendrimer transport. Concentrations at 10mM or above unlabeled G3.5 
and G4 dendrimers incubated with isolated rat intestine for 120 min appear to 
negatively impact jejunal and colonic mucosal morphology, TEER and 14C 
mannitol transport, indicating that these may be excessive concentrations for oral 
drug delivery applications in vivo. The Papp of FITC PAMAM dendrimers in Caco-
2 monolayers closely matches isolated jejunal transport. Colonic transport of 





Figure 4.6. Caco-2 permeability compared to isolated rat tissue transport of 
PAMAM dendrimers. Top panel: G4 dendrimer, bottom panel: G3.5 dendrimer. 
The comparative transport of Caco-2 cells to isolated tissue models displays 
the overestimation of rat colonic transport by Caco-2 cell culture transport. 
Caco-2 transport of PAMAM dendrimers more closely relates to rat jejunum 










































































epithelium. This study lays the groundwork for future work in PAMAM dendrimer 
oral drug delivery. The next Chapter is focused on using isolated human tissue 
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TRANSEPITHELIAL TRANSPORT OF PAMAM 
DENDRIMERS ACROSS ISOLATED 
HUMAN INTESTINAL TISSUE 
 
5.1 Introduction 
 PAMAM dendrimers are a class of polymeric nanoparticles that have 
shown potential in drug delivery (Figure 5.1).1–3 These constructs have a hyper-
branched structure that allows for the attachment of multiple therapeutic and 
imaging moieties to surface groups.4 They are synthesized with repeating 
alternating units of ethylene diamine and methyl methacrylate.5 The surface 
charge of dendrimers can be controlled based on functionalization of dendrimer 
termini with carboxyl, amine or hydroxyl groups. The hydrophilic structure of 
dendrimers can be utilized to enhance the solubility and intestinal permeability of 
drugs covalently attached or admixed with dendrimers.6,7 These properties 
provide rationale for the application of PAMAM dendrimers in drug delivery. 
 Given their macromolecular nature, appreciable transport across intestinal 
epithelial barrier has been observed providing rationale for the development of 
PAMAM dendrimers as oral drug carriers.3,8 Dosing of drugs via the oral route 






Figure 5.1. Challenges to dendrimer oral drug delivery lie in the transepithelial 




preference, cost-effectiveness and enhanced patient quality of life.9 PAMAM 
dendrimers have the ability to enhance the oral permeability of drugs based on 
previous work in Caco-2 cell culture, isolated tissue and in vivo models.1–3,6,8,10–12 
Dendrimer transport in Caco-2 monolayers has been observed to be size, 
charge, concentration and incubation-time dependent.10,11 The transepithelial 
transport of dendrimers ranging from generation 1 (G1) to generation 4.5 (G4.5) 
has been observed in Caco-2 studies. The apparent permeability (Papp) was 
observed to vary with increasing generational size in anionic G1.5-3.5 
dendrimers.10,13 Rates of transport were also found to increase with increasing 
incubation time for positively charged G0 and G1 dendrimers in Caco-2 
monolayers.10 The Papp of G3.5-FITC labeled dendrimers was found to be ~6×10-
6 cm/s at 120 min incubation times and 1.0mM concentrations in Caco-2 cells.13 
Concentrations of anionic G3.5–COOH terminated dendrimers greater than 
1.0mM were found to be toxic via lactose dehydrogenase (LDH) release in Caco-
2 cells at 150 min incubation times.14 Cationic G4-NH2 dendrimers were found to 
be toxic at concentrations of 0.1mM via LDH release, unless surface groups were 
substituted with neutral of hydrophobic moleceules.10,15 Kitchens et al. noted that 
1.0mM G4-FITC dendrimers with a 1:8 loading ratio and 120 min incubation time 
did not induce cytotoxicity via the WST-1 assay. The Papp of this compound was 
~24×10-6 cm/s.13 
Work in everted rat intestinal tissue models has found that the endocytic 
index of PAMAM dendrimers was higher for anionic G5.5 PAMAM dendrimers 




G3.5-FITC labeled dendrimers were found to have a permeability higher than 
that of control and G4-FITC dendrimers at 1.0mM concentrations in isolated rat 
jejunum mounted in Ussing chambers.2 Further work in isolated tissue models 
using rat jejunum has shown that 1.0mM concentrations of G3.5 and G4 
dendrimers caused no significant damage to isolated tissue compared to 
controls. Discrepancies in the toxic concentration of G4 dendrimers between 
Caco-2 cells and isolated rat intestinal models may be due to the lack of mucous, 
morphology and other factors present in isolated tissue models.  
Further research in vivo has shown that PAMAM dendrimers are able to 
cross the intestinal epithelium and enter the systemic blood circulation. 
Thiagarajan et al. observed an oral fraction absorbed of 9.4% in CD-1 mice 
dosed with G6.5 anionic dendrimers.1 Evidence also exists that PAMAM 
dendrimers have the ability to enhance the permeability of drugs mixed with or 
encapsulated in dendrimers. Sadekar et al. noted the ability of PAMAM 
dendrimers to increase the oral area under the curve (AUC) of camptothecin two 
fold when dendrimers were dosed at 1000mg/kg (~7mM intestinal concentration) 
to CD-1 mice.6 Additional studies on the intestinal morphology after said 
treatment noted a lack of histopathological changes in the villi structure. 
While these cell culture and animal studies have established the 
groundwork for PAMAM dendrimer oral delivery, translation into clinical use has 
not yet been accomplished. Significant differences exist between human, rat and 
Caco-2 permeability studies including transport proteins, metabolic proteins, 




predict the human intestinal permeability of PAMAM dendrimers based on 
isolated human tissue results.24 This information will provide predictions of the 
applicability of PAMAM dendrimer drug delivery systems (or lack thereof) based 
on the permeability values obtained from human isolated tissue as well as a 
basic understanding of the macromolecular relationship between Caco-2, rat and 
human permeability experiments using PAMAM dendrimers as a test probe. 
 
5.2 Materials 
Fluorescein isothiocyanate (FITC), fluorescein isothiocyanate dextrans, N-
(3-dimethylaminopropyl)-N’-ethylcarbodiimide (EDC) were obtained from Sigma 
Aldrich (MO, USA). 14C mannitol (0.1mCi/mL in sterile water) was obtained from 
American Radiolabeled Chemicals (MO, USA). PAMAM dendrimers (G3.5 and 
G4.0) were obtained from Dendritech, Inc. (MI, USA). All other reagents were 
obtained from VWR. 
 
5.3 Methods 
 FITC labeled dendrimers (G3.5 and G4) were synthesized as reported 
previously.13 PAMAM dendrimers that had carboxyl termini were first modified 
with ethylenediamine to create sites for FITC attachment. G3.5 dendrimers were 
reacted with EDC and ethylenediamine in PBS pH 7.4 followed by overnight 
stirring and then addition of FITC (<5mg/mL in acetone) to the amine modified 
dendrimer. G4 dendrimers were mixed with FITC in acetone and PBS. All 




by size exclusion chromatography (SEC) using a fast protein liquid 
chromatography (FPLC) system (GE Lifesciences, NJ, USA) on a preparative XK 
26/70 column packed with Superdex 30 media. Final characterization of the 
fluorescent compounds was carried out using SEC on FPLC with a Superose 6 
column (GE Lifesciences, NJ, USA) with PBS as an eluent to verify the absence 
of free label. 
Human tissue use was approved by the University of Utah Institutional 
Review Board (IRB protocol #10924). Isolated jejunum and colon segments were 
received from colectomy, pancreaticoduodenectomy and Roux-en-Y gastric 
bypass surgery patients with informed consent from each patient. The patient 
population age ranged from 19 to 87 years of age with an average age of 58 
(Table 5.1). 
 The majority of patients donating colon tissues were undergoing treatment 
for cancer. Bariatric surgery was the primary source of jejunal epithelium and 
thus it came from non-cancer bearing patients. Samples were in general cancer-
free and non-inflamed. Any necrotic, inflamed or cancerous tissue was removed 
by the hospital pathology department prior to disbursement for use. One tissue 
segment was confirmed by pathology to contain cancerous tissue and was 
subsequently excluded from the study.  
Healthy tissue samples obtained from surgeries were immediately 
immersed in ice cold oxygenated Krebs-Hensleit (KH) buffer at pH 7.4 after 
disbursement and transported to the lab for mounting. All further dissection was 




Table 5.1. Patient statistics and transport time of the  
intestinal samples used in the study. 
 
Age (yrs) N= Gender Ratio (M/F) 
Time to Lab 
(H:MM) 
Jejunum 47 ± 13 11 0.57 0:19 ± 0:06 
Ascending 
Colon 
65 ± 19 4 0.67 0:16 ± 0:02 
Transverse 
Colon 
62 ± 15 14 0.56 0:28 ± 0:14 
Sigmoid Colon 55 ± 16 6 1.67 0:23 ± 0:08 
Males 55 ± 18 
 
- 0:21 ± 0:07 
Females 60 ± 14 
 
- 0:24 ±0:14 





bubbling of 95% O2/5% C02. The external muscularis layer was dissected away 
and the remaining epithelium was mounted in Ussing chambers with P2304 
inserts (Physiolgic Instruments, CA, USA) and an exposed surface area of 0.3 
cm2. Chambers were filled with 5mL of 37°C Krebs-Hensleit buffer gassed with 
95% O2/5% CO2 and equilibrated for 45 min prior to application of treatment. At 
time t=0min solutions containing test probes were added to the apical side of the 
chambers. Unlabeled dendrimers were added at concentrations of 0.1, 1.0, or 
10mM. All fluorescently labeled dendrimers were added at a concentration of 
1.0mM. Triton X100 was added at a 10% v/v concentration. All experiments 
included 5µL of 14C-mannitol. The apical and basolateral side of the chambers 
were sampled (200µL) at t=0 min and volume was replaced with KH buffer 
warmed to 37°C and oxygenated to maintain constant volume. The apical side 
was sampled at t=0 and 120 min while the basolateral side was sampled at t=0 
min followed by 20 min intervals for 120 min. Samples were analyzed using 
spectrophotometry (Spectramax M2, Molecular devices, CA, USA) and liquid 
scintillation (LS-6000IC, Beckman, CA, USA). 
TEER was measured using Evom-2 TEER measurement device (Warner 
Instruments, FL, USA) attached to AgCl electrodes (Physiologic Instruments, CA, 
USA) that were previously filled with a 3% agar solution made in 3 M KCl. TEER 
measurements were taken 15, 10 and 0 min before treatment and every 5 min 
after treatment began for the initial 20 min. Following the initial 20 min, TEER 
was measured every 20 min for 2 h. TEER results were analyzed using a 




At the end of the experiment the tissue was carefully removed from the 
chambers and fixed in buffered formalin. Tissues were mounted in paraffin blocks 
and stained using hematotoxilin and eosin (H&E).25 
Statistical analysis of the Papp data was compared using ANOVA, with 
Tukey’s post analysis in GraphPad® Prism (version 6.0c, CA, USA). TEER 
values were compared to control using one-way student’s t-test. 
 
5.4 Results 
Human tissue samples were obtained from the campus tissue repository 
approximately 50 min after removal from the patient. Samples were obtained and 
then transported to the lab in the times listed in Table 5.1. Control mannitol 
permeability and TEER values obtained for jejunum and colon tissue were within 
expected ranges based on previous literature.24 Tissue maintained morphological 
structure as noted by histological evaluation of the epithelial barriers. Mild edema 
was noted throughout the tissue specimens retrieved from Ussing chambers 
which is likely a result of the removal of lymphatic drainage in isolated tissue 
models. Overall the tissue morphology and integrity was intact as evidenced by 
mannitol, TEER and histological evaluation and in accordance with previous 
literature on similar experimental methods (Figures 5.2, 5.3, 5.4 and 5.5).26 
The permeability of PAMAM dendrimers was evaluated in this study along 
with the penetration enhancing effects on the small paracellular marker mannitol. 
G3.5 and G4 PAMAM dendrimers did not cause a statistically significant increase 






Figure 5.2. PAMAM dendrimer mannitol permeability in human intestinal 
epithelium; top panel: colon, bottom panel: jejunum. The permeability of 
mannitol was significantly increased compared to control by G4 10mM 
treatments in human colon (p<0.05). Mannitol permeability in human jejunum 
trended toward increased permeability at higher concentrations of dendrimers, 
but this increase was not statistically significant (n=3-19); * signifies 
statistically significant from control, FD4=4kDa FITC dextran, FD10=10kDa 















































































Figure 5.3. Percent TEER values for human colonic and jejunal mucosae. Top 
panel: colon, Bottom panel: jejunum; (mean ± standard error of mean, * 







Figure 5.4. Human jejunum histology in the presence of 0.1mM, 1mM and 
10mM PAMAM dendrimers. The histological evaluation of treatment of human 
tissue with PAMAM dendrimers showed significant reduction in the crypt-
villous axis tissue thickness when treated with 10mM concentrations of G3.5-
COOH and G4-NH2 dendrimers. G3.5-COOH and G4-NH2 dendrimers at 
0.1mM and 1.0mM concentrations did not cause a significantly observable 
reduction in thickness of the epithelium along the crypt-villous axis (top to 
bottom). ((A), (E) controls; (B) 0.1mM G3.5; (C) 1mM G3.5; (D) 10mM G3.5; 







Figure 5.5. Human colon histology in the presence of 0.1mM, 1mM and 10mM 
PAMAM dendrimers. Colonic epithelium was similarly affected by PAMAM 
dendrimers as jejunal isolated tissues. The tissue thickness was reduced with 
high concentrations of PAMAM dendrimers (D, H). Minor sloughing of 
epithelial cells and edema was noted in all samples including controls. This 
sloughing of epithelial cells from the surface was significantly greater in 
tissues treated with 10mM concentrations of dendrimers. ((A), (E) controls; (B) 






and colonic tissues. Ten mM concentration of G4 dendrimers caused a 
significant increase in mannitol permeability compared to control in human colon 
tissue, but not in human jejunum (Figure 5.2). 
FITC-labeled PAMAM dendrimer permeability was not statistically different 
from free FITC in jejunum and colonic epithelium. G3.5 and G4 FITC labeled 
dendrimers (1.0mM) trended above the control in colonic segments, but did not 
attain a statistically different value from control. The permeability values for G3.5-
COOH and G4-NH2 dendrimers in human colon was 3.65x10-6 cm/s and 2.08 
x10-6 cm/s, respectively. The Papp for G3.5-COOH and G4-COOH dendrimers in 
jejunal tissue was 2.11 x10-6 cm/s and 0.96 x10-6 cm/s, respectively (Figure 5.6).  
TEER values at t=0 min were an average of 54±25 ohms-cm2 and 150±73 
ohms-cm2 for colon and jejunum, respectively. TEER values in colonic and 
jejunal mucosae did not differ from the control for G3.5 and G4 PAMAM 
dendrimers at 1.0mM concentrations. This is similar to previous data obtained in 
rat epithelium.2 A reduction of 50% of the initial TEER value was not achieved for 
any samples excluding the positive control Triton X100. 
Histological evaluation of the tissue noted the apparent sloughing of cells 
off the epithelial surface at 10mM concentrations of G3.5 and G4 dendrimers. 
Both of these probes caused significant reduction in the epithelial thickness at 
10mM concentrations compared to 0.1 or 1mM concentrations and control. The 
apparent change in epithelial thickness along the crypt to villous axis is likely due 
to the negative interaction of 10mM concentrations of dendrimers with epithelial 






Figure 5.6. Apparent permeability of PAMAM dendrimers across isolated 
human intestinal tissue; top panel: colon, bottom panel: jejunum. G3.5-FITC 
was observed to have the highest Papp of the groups tested in colonic and 
jejunal segments. No significant differences were observed. (n=3-6, 
FD4=4kDa FITC dextran, FD10=10kDa FITC dextran, mean ± standard error 








































epithelium disruption when treated with 10mM concentrations of G3.5-COOH and 
G4-NH2 dendrimers. The deeper layers of epithelium closer to the lamina propria 
remained intact even at 10mM concentrations of dendrimer (Figure 5.5, 5.6). 
 
5.5 Discussion 
PAMAM dendrimers’ oral delivery is highly dependent on their 
permeability across the intestinal epithelium. The intestinal barrier blocks 
hydrophilic macromolecules from penetrating the epithelium and entering 
systemic circulation.27–31 Substantial absorption across the gastrointestinal tract 
in rat models was observed suggesting the potential for improving the delivery of 
highly potent drugs with limited oral bioavailability. These studies were done in 
cell culture and animal models, which lack many aspects of human intestinal 
epithelium.16,19,20,32 The next logical step was to test their permeability across 
human tissue. In this study we used isolated human intestinal tissue to evaluate 
PAMAM dendrimer transepithelial transport. 
Consistent with previous reports, only minor changes were observed in 
intestinal morphology from fresh tissue and tissue after being treated in Ussing 
chambers for the experimental time frame of 120 min.33,34 Slight edema 
appeared in all sections treated in Ussing chambers that corresponded with the 
lack of lymphatic drainage in this set up, but this did not inhibit the viability of the 
tissue as previously observed.26  
Significant differences were noted between previous Caco-2 and isolated 




any treatment group compared to control, except the positive control Triton X100. 
Previously we noted that concentrations as low as 0.1mM of G4 PAMAM 
dendrimers caused a reduction in TEER in Caco-2 monolayers. This 
concentration is 10 fold lower than concentrations used in this study.10,14 Caco-2 
cells are thus noticeably more sensitive to reductions in TEER than isolated 
tissue models. These results are confirmed by previous isolated rat intestinal 
tissue results using 1mM concentrations of G3.5 and G4 dendrimers.2  
The discrepancy between Caco-2 cells and isolated tissue extends to their 
morphology. Previously we had shown that positively charged G4-PAMAM 
dendrimers cause significant damage to Caco-2 microvilli at 1mM concentrations 
for 120 min incubation times.35 In human isolated tissue no such morphological 
changes occurred at similar concentrations and incubation times for G3.5-COOH 
and G4-NH2 dendrimers. This difference between the maximum tolerated 
concentrations of dendrimers rationalizes the use of isolated tissue models for 
understanding epithelial toxicity and transport. The difference between Caco-2 
and isolated tissue models may be caused by the lack of mucous, supportive 
cells and morphology which are present in isolated tissue models.17,36,37  
The permeability of mannitol was significantly increased in colonic 
epithelium treated with G3.5-COOH and G4-NH2 dendrimers at 10mM 
concentrations. 10mM concentrations did not however significantly enhance the 
mannitol permeability in jejunal segments. Colonic epithelium have been noted 
for the increased sensitivity to penetration enhancement and this may be the 




may contribute to this enhanced sensitivity may be the heightened ability of 
colonic tissue to absorb water and electrolytes which may drag dendrimers into 
close proximity with epithelial layers and modulate tight junction opening and 
enhanced mannitol transport. One mM and 0.1mM concentrations of PAMAM 
dendrimer caused no significant changes in mannitol transport in colonic 
epithelium. 
Previous studies have noted the toxic effects of PAMAM dendrimers to 
epithelial barriers and in vivo organ systems.39–41 In vivo studies aimed at 
establishing the oral maximum tolerated dose (MTD) of PAMAM dendrimers 
found that G3.5 and G4 dendrimers could be given at 300 mg/kg to CD-1 mice 
with no adverse events.42 A 300 mg/kg dose of G4-NH2 and G3.5-COOH 
dendrimers is roughly equal to 1-2mM concentration at the site of the small 
intestine (estimated 2 fold intestinal dilution factor and 200µL gavage volume). 
Thus previous MTD studies agree with results here where there are no significant 
changes in intestinal morphology, TEER and mannitol Papp at 1mM 
concentrations of G4-NH2 and G3.5-COOH. Interestingly, doses of 1000mg/kg of 
G3.5 dendrimer (~4-7 mM epithelial concentration) given to CD-1 mice have also 
been observed to cause no morphological changes to epithelial barriers and no 
increase in mannitol absorption after 4 h treatment.6 The signs of intestinal 
morphology damage and increased mannitol permeability at 10mM 
concentrations of G3.5 dendrimers imply an oral MTD for G3.5 dendrimers 
between 1000-3000 mg/kg. This is based on extrapolation of the 10mM 




based on variations in residence time in the gastrointestinal tract and dilution 
factors which are not represented in the Ussing chamber model. Nonetheless 
this MTD would not be surprising, since the lethal dose 50 (LD50) of chitosan and 
polyacrylic acid is 1.5g/kg and 2.5g/kg, respectively.43,44  
The results of this study conclude that concentrations of 10mM dendrimer, 
regardless of surface charge or region, caused changes in epithelial morphology 
and TEER in isolated human intestinal epithelium. Ten mM concentrations of 
G3.5 and G4 dendrimers may cause damage to the surface epithelial layers due 
to the pore-forming nature of PAMAM dendrimers within epithelial layers as 
investigated by molecular dynamic simulation.45  
Previous data from our lab have established the Papp in rat and Caco-2 cell 
cultures.2 Small and large molecular weight compounds appeared to have 
distinct model dependent trends (Figure 5.7). Rat and human FITC Papp closely 
corresponded. FITC Papp was overestimated by Caco-2 monolayers compared to 
human intestinal Papp. While the wide variability of Caco-2 studies has been 
noted in the literature, results points out an overestimation of Papp for small 
molecular weight drugs compared to human intestinal transport.46 
The transepithelial transport of 4kDa dextran in human jejunum and colon 
was similar to Caco-2 results. However, G3.5 and G4-FITC labeled dendrimers’ 
Papp was overestimated by both rat jejunum and Caco-2 models. This trend may 
be due to the lack of mucous in Caco-2 monolayers which may interact with 
dendrimers and inhibit their transport. Such mucous interaction may be 






Figure 5.7. Comparison of Caco-2, and isolated rat and human intestinal 
permeability (A – FITC, B – 4kDa FITC dextran, C – G3.5-FITC, D – G4-
FITC). Papp of the respective marker in human and rat jejunum and colon, and 
Caco-2 models was compared. Caco-2 and rat jejunum Papp tend to 
overestimate human Papp. Rat jejunal permeability from Ref. 2. Rat colonic and 
Caco-2 data are unpublished data. (* represent p<0.05 between groups 









































































































































































































The overestimation of dendrimer transport by isolated rat jejunum may be 
due to the wide difference in number of follicles per cm2 of intestinal tissue (0.03 
follicles/cm2 versus 2.1 follicles/cm2 in human and rat small intestine, 
respectively).22,47 This may represent an interesting trend in dendrimer 
transepithelial transport, as enhanced transport of nanoparticles through Peyers 
patch tissue has previously been noted and may have an effect on dendrimer 
transport as well.48 Further experimentation in this area is warranted. Other 
differences may be due to the large variation between rat and human cell surface 
protein expression, and effective surface area.49 
Isolated human tissues in Ussing chambers have been observed to have 
a strong correlation to human fraction absorbed.24 For this reason we have 
evaluated PAMAM dendrimer permeability across isolated human tissue. The 
permeability of PAMAM dendrimers across isolated tissue reveals important 
aspects of their transepithelial transport. In the present study the permeability of 
G3.5 and G4 PAMAM dendrimers in human isolated jejunum was found to be 
2.1×10-6 cm/sec and 0.96×10-6 cm/sec for G3.5 and G4 dendrimers, respectively. 
The colonic transport was found to be 3.65×10-6 cm/sec and 2.08×10-6 cm/sec for 
G3.5 and G4 dendrimers, respectively. If one were to estimate the fraction 
absorbed based on previous Lennernäs multilaboratory drug correlation curves 
established in human isolated tissue, the Papp would predict a fraction absorbed 
of roughly 30-45% in human jejunum and 10-15% in human colon.24  
The Lennernäs multilaboratory drug correlation study was a 12-year study 




donors across 3 different labs. This landmark study established a strong 
correlation between human intestinal permeability and human fraction absorbed. 
The rate of permeability though the intestinal tract is a direct measure of the 
amount of drug penetrating through the epithelium (i.e., entering systemic 
circulation) and thus the correlation is highly accurate. The value of permeability 
in human jejunum attained in this study was very high considering the 
macromolecular nature of PAMAM dendrimers. It was also high in rat intestinal 
tissue as shown in Chapter 2 and 3, and previous studies in other labs.3 Other 
proteins (ovalbumin, α-lactalbumin), and polymers (4.4kDa Dextran, 70 kDa 
dextran, 4 kDa PEG) have a Papp ranging from 0.01-0.1×10-6 cm/s.50 Observed 
fraction absorbed for these macromolecules is exactly as predicted by the 
Lennernäs paper.29,51,52 This provides evidence that the correlation remains valid 
for macromolecules.  
The Lennernäs correlation curves are made from Papp of small molecular 
weight pharmaceuticals and have limitations when extrapolated to PAMAM 
dendrimers. The prediction of fraction absorbed using small molecular weight 
probes across the intestinal epithelial barriers has inherent assumptions that 
these probes are not influenced by endocytic mechanism such as which affect 
PAMAM dendrimer transport. Our previous in vitro studies showed that PAMAM 
dendrimers are endocytosed and thus may have exceptional properties, which 
may limit the prediction of fraction absorbed. In addition PAMAM dendrimers are 
known to have penetration enhancing effects and open the tight junctions. As has 




This predicted fraction absorbed is based on correlation curves made from 
Papp of small molecular weight pharmaceuticals and has limitations when 
extrapolated to macromolecules such as PAMAM dendrimers. It must be noted 
that the prediction of fraction absorbed using small molecular weight probes 
across the intestinal epithelial barriers has inherent assumptions that these 
probes do not influence the transport properties of epithelial barriers, whereas 
from our previous in vitro studies it is known that PAMAM dendrimers interact 
with the epithelial barriers, modulate tight junctions and are transported by a 
combination of paracellular and transcellular route.10 It has already been 
observed that dendrimers are endocytosed into the intracellular compartment, by 
Caco-2 studies.53 This could lead to inaccuracies in estimating fraction absorbed 
based on small molecular weight transport studies as such processes can be 
saturated and contain a nonlinear dose dependent permeability values. 
Additional studies into the apical-basolateral (AB) versus basolateral-apical (BA) 
Papp need to be performed in order to evaluate the apparent intrinsic permeability 
of the dendrimers, especially since differential AB and BA Papp has already been 
observed in Caco-2 monolayers.10 Therefore the above predicted values for oral 
absorption can potentially be highly biased and realistically can only be 
ascertained when administered to human subjects. Overall a predicted fraction 
absorbed for 13-14 kDa dendrimers of 30% in humans is relatively large when 
compared to the fraction absorbed of 4 kDa PEG of 0.4%, and may be an 
overestimation29,51 (Table 5.2). 




Table 5.2. Comparison of Papp ×10-6 and % absorbed of various 
macromolecules in literature and this study (aestimated values).24,29,60–62 








 Mannitol 3.07 5.90 
 
G3.5-FITC 2.10 3.65 35a 
G4-NH2-FITC 0.96 2.08 11a 












Mannitol60,62 5.56 4.95 38 
Ovalbumin60 0.02 0.02 0.1a 
α-lactalbumin60 0.11 0.01 0.1a 
4 kDa Dextrans60 0.15 0.10 0.1a 
70 kDa Dextran60 0.01 0.01 0.1a 





drug delivery, especially if the attached drug is highly potent and the 
biodistribution can be modified to passively or actively target the site of 
action.54,55 This research focus has been explored by our lab and others.56–58 For 
example, G3.5-SN38 compounds have been previously synthesized.56 If one 
were to estimate the blood concentration of dendrimer-drug conjugates, based 
on a modest oral dose of 2 mg/kg in a 70 kg human with a fraction absorbed of 
30% this would give an estimated serum concentration of 0.6 µM (42 mg of G3.5-
SN38, in 5L plasma volume). This matches the previously reported IC50 value of 
G3.5-SN38 in HT-29 cell cultures.7 These results show that dendrimer drug 
conjugates could potentially be therapeutically effective as an oral drug delivery 
system for highly potent drugs with IC50 values less than 1 µM. 
 
5.6 Conclusion 
The permeability of PAMAM dendrimers across intestinal epithelial barrier 
models has been evaluated in Caco-2 monolayers, 8,10,13–15 isolated rat intestinal 
tissue,3,38 in vivo to rats42 and mice1,6 and in isolated human tissues as reported 
here. Of note was the permeability of PAMAM dendrimers ranging from 2.1×10-6 
for G3.5 probes in isolated human jejunum. The permeability of PAMAM 
dendrimers is 4 fold higher than other 4 kDa dextran tested in human isolated 
jejunum, and has an estimated fraction absorbed 100 fold higher than 4 kDa 
PEG polymers.29,51 The regional dependence of G3.5 and G4 PAMAM dendrimer 
transport has been established, with demonstrated highest rate of transport in 




and Caco-2 monolayers has specifically demonstrated an overestimation of 
dendrimer Papp by isolated rat and Caco-2 models.  
The change in intestinal morphology caused by PAMAM dendrimers 
appears to correlate with previous in vivo toxicity studies, but not with previous 
Caco-2 models. This potentially provides a dosing window of opportunity where 
dendrimer drug delivery can be developed.6,42 Specifically an estimated MTD of 
1000-3000 mg/kg is implied by the changes in epithelial morphology noted at 
10mM concentrations in human isolated tissue.  
Despite residing in the BCS class for low permeability, the attachment of 
highly potent drugs may still benefit from the enhanced permeability that PAMAM 
dendrimers can offer. The potential localized release of PAMAM dendrimer-drug 
conjugates could enhance efficacy and safety of the drug, while simultaneously 
providing an oral formulation. Future developments utilizing PAMAM dendrimers 
for oral drug delivery may focus on attaching highly potent drugs that otherwise 
have dose limiting toxicity or solubility. 
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6.1 Oral drug delivery 
In this dissertation, PAMAM dendrimers were evaluated as nanocarriers 
for delivery via the oral route. The hypothesis in the first part of this dissertation 
was that PAMAM dendrimer permeability through isolated rat intestinal tissue 
was significantly higher than similar sized dextran molecules and free fluorescein 
isothiocyanate (FITC). This result was confirmed in the study with generation 3.5 
(G3.5) PAMAM dendrimer transport being significantly greater than free FITC.1 
G3.5 and G4 PAMAM dendrimer transport trended higher than 4 kDa FITC-
dextran as well confirming their appreciable permeability in isolated rat intestinal 
tissue. 
Corollary to the first hypothesis was that 1 mM concentrations of PAMAM 
dendrimer would not cause significant epithelial damage to isolated rat intestinal 
tissue. Previous work in Caco-2 models showed significant difference in 
concentration and incubation time dependent effects on epithelial morphology 
between Caco-2 and in vivo models.2–5 This result was confirmed by two 
separate studies utilizing supratoxic Caco-2 concentration of PAMAM dendrimers 




result confirms that Caco-2 cells are more sensitive to PAMAM dendrimer 
induced changes in intestinal morphology than Caco-2 or in vivo models.1,6 
This result led to the evaluation of PAMAM dendrimer concentration at 
which morphological changes occur in isolated intestinal tissue. Previously the 
maximum concentrations observed at which morphological changes and lactate 
dehydrogenase release did not occur were less than 0.1 mM for G4 PAMAM 
dendrimers and less than 1mM for G3.5 dendrimers (120 min incubation 
times).5,7 This result was found to be significantly higher in isolated rat intestinal 
tissue, where neither G3.5 nor G4 dendrimers caused morphological changes 
until 10 mM concentrations were reached.6 This difference was assumed to be a 
function of the difference between Caco-2 and isolated tissue models including 
mucous layers, enzyme expression and morphological properties. 
Aim 2 of this dissertation focused on the regional difference between 
PAMAM dendrimer transport in isolated rat intestinal tissue. Colon and jejunum 
samples were observed to have differential rates of transport for PAMAM 
dendrimers. G3.5 and G4 PAMAM dendrimer transport was significantly higher in 
isolated jejunal mucosae than in colonic mucosae.6 This is not surprising 
considering the thicker mucous and reduced surface area of the rat colonic 
epithelium.5,6 Interestingly, the permeability in rat intestinal jejunum was found to 
have comparable results with Caco-2 studies, but not with rat colonic 
permeability. Caco-2 cells are generally considered to have characteristics of 
small bowel similar to the large intestine.8  




the physiological factors mentioned previously and also the reduced thickness of 
single monolayers compared to isolated intestinal tissue. Further analysis of the 
comparison between Caco-2 and rat isolated intestinal epithelium noted key 
differences in TEER and mannitol permeability in the presence of PAMAM 
dendrimers. TEER was significantly reduced in Caco-2 models at 0.1 mM but no 
effect was observed at 1mM concentrations for G4 dendrimers.5,6 The influence 
of dendrimers on mannitol permeability was found to be significant at 0.01 mM 
for G4 dendrimers in Caco-2 cells, whereas concentrations as high as 1 mM 
caused no change in isolated rat intestinal tissue. G3.5 dendrimers caused an 
increase in mannitol permeability at 0.1 mM in Caco-2 cells, but were not found 
to cause a statistically significant increase in permeably at 10 mM in isolated 
intestinal tissue. This confirms the conclusion that PAMAM dendrimers are more 
sensitive to penetration enhancement than isolated or in vivo gastrointestinal 
physiology and adds evidence that penetration enhancing effects observed in 
Caco-2 monolayers should be treated with caution. 
The third aim of this dissertation was to address the permeability of 
PAMAM dendrimers in isolated human tissue and to predict a human fraction 
absorbed based on previously published correaltins.9 This resulted in the 
observation that G3.5 PAMAM dendrimer permeability through isolated jejunal 
tissue was 2.1× 10-6 cm/s. The estimated fraction absorbed for such a rate is 
~30%. This result is very high for a macromolecule of 12.9 kDa molecule and 
may be an overestimation since previous correlations were established for small 




are transported via endocytic routes and interact with the barrier to open tight 
junctions. Nevertheless this rate is significant especially when comparable size 
PEG molecules have a human fraction absorbed of 0.4%.10,11 While this does not 
allow PAMAM dendrimers to function as an oral drug delivery agent for all types 
of pharmaceuticals, it does allow the oral delivery of highly potent compounds. 
Highly potent cancer drugs may benefit from PAMAM dendrimer drug delivery, 
drugs that with an IC50 greater than 1µM are predicted to not reach a viable blood 
concentration for therapeutic delivery 
The comparison of PAMAM dendrimer permeability between Caco-2 rat 
and isolated tissue models led to the conclusion that Caco-2 and rat models 
generally overestimate human absorption in the jejunum epithelium for PAMAM 
dendrimers. Dextran transport was noted to be similar between human, rat and 
Caco-2 models, showing that the compact molecular architecture of PAMAM 
dendrimers may have significant impact on biodistribution and oral absorption. 
This result has been confirmed previously by head to head studies with N-(2-
hydroxypropyl)methacrylamide (HPMA) copolymers and PAMAM dendrimers.12 
PAMAM dendrimer permeability and oral absorption may be facilitated by their 
compact structure and smaller hydrodynamic radius than other linear polymers, 
in addition to opening tight junctions and cellular uptake by endocytosis.  
This research did not include any drug molecules in the studies of 
transepithelial transport. This impacts this research in two ways. First, since 
attachment of drug molecules could potentially alter transport, avoiding them 




intestinal barrier. Understanding the transepithelial transport of PAMAM 
dendrimers was a necessary precursor to understanding the positive (or 
negative) effects of drug attachment on permeability. Second, avoiding the use of 
a drug in these studies decreased the impact on clinical drug delivery. Previous 
research has observed the ability of PAMAM dendrimers to increase drug 
transport through the intestinal epithelium as mentioned in Chapter 2, so this was 
not the primary focus of this dissertation.2,13  
Based on this research in isolated human intestinal tissue it is estimated 
that drugs that have an IC50 <1µM should be investigated for oral drug delivery. 
Estimations from this study show that PAMAM dendrimer transport may be 
capable of delivering a drugs at an appreciable rate, but probably not sufficient 
for low potency compounds with an IC50  >1µM.  
 
6.2 Future directions 
Future directions of this research include studying intestinal transport of 
PAMAM dendrimers through isolated tissue in a dose depended manner and 
verifying their transport in the apical to basolateral and basolateral to apical 
direction. This would allow a greater understanding of the maximum permeability 
of PAMAM dendrimers and key insight into the serosal transport properties of 
dendrimers (whether active or passive).  
Attempts should be made to attach highly potent (IC50 <1µM) small 
molecular weight drugs for oral delivery. This will significantly enhance the 




likely to exceed 1µM. Efficacy and safety of these systems will have to be 
evaluated on a case by case basis to assure reduced toxicity of polymeric 
delivery does not also reduce the efficacy of the attached therapeutic agent and 
diminish the effect of the treatment.14 Therapies that are high on the list of 
potential candidates for drug delivery include highly potent anticancer drugs such 
as SN38, docetaxel and gemcitabine. Some of these drugs are administered via 
10 h or more infusions for patients. Thus an oral formulation of these drugs would 
strongly benefit patient quality of life. 
Future studies may evaluate a range of penetration enhancers to find the 
best match for PAMAM dendrimer oral drug delivery.15 These studies should be 
carried out in isolated tissue models to assure realistic values of Papp are 
obtained. Combinatorial studies in isolated tissue may be necessary to evaluate 
the wide spectrum of penetration enhancers available. Enhancers that do not 
damage the intestinal morphology, do not sequester dendrimers, and aid in 
enhancement will be ideal in order to find a safe and effective delivery strategy. 
In order to carry out studies in isolated tissue at a higher rate, high 
throughput Ussing chambers may be of use. Both the sheer volume required for 
standard Ussing chambers and format of the tissue chambers for mounting the 
tissue was found to be limiting. A potential high throughput, low volume Ussing 
chamber would greatly enhance this study and allow for much more rapid 
analysis of the hypothesis posed. Comparative studies would be required 





Drugs that have an IC50 <1µM should be investigated for oral drug 
delivery. Estimations from this study show that PAMAM dendrimer transport may 
be capable of delivering drugs at an appreciable rate, but probably not sufficient 
for low potency compounds with an IC50 above 1µM.  
Future studies should specifically focus on the attachment of SN38, 
gemcitabine or docetaxel to PAMAM dendrimers for the development of oral drug 
delivery. Docetaxel is already used to treat many patients, so adding a novel oral 
formulation to the possible routes of administration could be potentially benefitial. 
Additionally there already exist industry partners developing Priostar™ 
dendrimers for intravenous therapy of docetaxel. Their promising results from 
phase I clinical trials may be helpful for establishing dendrimer oral drug delivery 
although the chemical composition does not exactly match.16–18  
Bioconjugation strategies for drugs with PAMAM dendrimers may focus on 
the critical step where drugs are attached to dendrimers. Attaching various linker 
molecules has not been a major issue due to the similarity in polarity of the 
linkers and dendrimers. Generally the drugs used do not have the same polarity 
as dendrimers and thus have made finding an appropriate solvent system 
difficult. Future research may focus on DMF soluble drugs. Additionally HBTU 
activation may be better able to activate –COOH than carbodiimide activation 
agents for bioconjugation. Achieving the right drug-dendrimer molar ratio will be 
important so as to still remain soluble in aqueous systems (too much drug 
attachment may cause the dendrimer to precipitate in water). 




cancer cell lines and intestinal epithelial cell lines would be primary targets for 
cytotoxicity assays. The cytotoxicity studies should focus on testing IC50 values in 
these models. 
Following cytotoxicity evaluation the transepithelial transport in Caco-2 
cells, isolated rat and isolated human tissue should be observed to assure the 
permeability of dendrimer drug conjugates is still sufficient for oral drug delivery. 
Attachment of drugs could change the rate of absorption. 
These studies should be followed by in vivo toxicity and efficacy studies in 
mice or rats. Penetration enhancers may be required to achieve efficacy, and 
potentially sodium caprate or other commonly used enhancers could be used to 
achieve efficacy in animals. These combinations would also need to be checked 
for toxicity in the same model systems at the same dosages as used in efficacy. 
Potentially the dendrimer drug system will not require a penetration enhancer 
and efficacy would be sufficient without it. 
The critical problems that need to be resolved for clinical development of 
PAMAM dendrimer drug conjugates are: 
1) PAMAM dendrimers have a wide batch to batch variability requiring 
characterization and purification of every lot. This inconsistency would be 
unacceptable for a clinically approved candidate in terms of reproducibility and 
good manufacturing practice.19 While much has been done to improve dendrimer 
synthesis, novel strategies using microwave assisted synthesis may improve the 
kinetics of dendrimer reactions (that normally take days to weeks to complete) 




would be to purify in bulk all compounds received on an industrial scale to 
remove all smaller generations and other impurities. 
2) Dendrimer conjugation with drug molecules has had inconsistencies 
that have made attachment of drugs difficult. Low drug loading and a lack of 
appropriate solvents for solubilization of dendrimer-drug reactions have made the 
synthesis exceedingly difficult. This problem may be offspring of the previously 
mentioned dendrimer batch to batch variability, but has not been resolved fully, 
and may be a function of the altered pKa of surface amine or carboxylic acid 
groups as mentioned in Chapter 2. The attachment of hydrophobic molecules to 
PAMAM dendrimers has been difficult to reproduce consistently and may need to 
be optimized in order to create a clinically viable macromolecule. This problem 
has been noted by other groups as well as our own.20 Reproducible synthetic 
methods for drug attachment is critical for consistent patient care and thus is 
required by the Food and Drug Administration for entrance into clinical trials. 
Other moieties such as imaging agents and targeting ligands will require the 
same characterization and reproducibility in order to facilitate clinical translation. 
3) Finally for a full scale clinical study to commence, good laboratory 
practice and good manufacturing practice must be implemented in a preclinical 
pharmacokinetic, safety and toxicity study. These studies must include 
absorption, distribution, metabolism, teratogenicity, efficacy, clearance and long 
term carcinogenic effects. Rats, mice and nonhuman primate models may be 
suitable for preclinical testing of these parameters to develop a safety and 




to a clinical stage where human efficacy can be tested. 
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EFFECT OF PEPTIDE PENETRATION ENHANCERS  
ON INTESTINAL PERMEABILITY  
OF PAMAM DENDRIMERS 
 
A.1 Introduction 
In spite of initial results showing appreciable permeability of PAMAM 
dendrimers across rat epithelium, the human intestinal permeability was found to 
be significantly lower,1 limiting dendrimer drug delivery to highly potent drugs.1 
While this level of delivery is significant, it is not sufficient for delivery of less 
potent drugs which require a larger fraction absorbed.2 In order to increase the 
therapeutic impact of PAMAM dendrimer oral drug delivery we explored the use 
of penetration enhancers for improving dendrimer permeation across the 
intestinal epithelium. 
Specifically we have looked into the physical mixtures of the P640 peptide 
penetration enhancer with the structure RRVEVKYDRRKKR (one letter amino 
acid sequences used) with dendrimers. This sequence investigated by Dr. 
Randall Mrsny of University of Bath is a myosin light chain phosphatase 
inhibitor.3–7 Its mode of action is through inhibiting the dephosphorylation of 




myosin cytoskeleton and opening of the tight junction pores.7,8  
 
A.2 Experimental methods 
A.2.1 Materials 
Reagents for solid phase amino acid synthesis were obtained from 
AAPTEC (KY, USA). Fluorescein isothiocyanate (FITC) (cat. no. F7250), 
fluorescein isothiocyanate dextrans (cat. no. FD10S), and Canadian origin fetal 
bovine serum (FBS) were obtained from Sigma-Aldrich (MO, USA). PAMAM 
dendrimers (G3.5-COOH, and G4.0-NH2) were obtained from Dendritech, Inc. 
(Michigan, USA). 14C mannitol (0.1mCi/mL in sterile water) was obtained from 
American Radiolabeled Chemicals (MO, USA). Cells were obtained from 




6.2.2. Synthesis and characterizations 
RRVEVKYDRRKKR sequence was synthesized using solid phase peptide 
synthesis. Briefly to a preswelled Arginine-loaded Wang resin (0.3mmol/gram 
loading) was added a solution of 20% v/v piperidine in anhydrous amine-free 
dimethyl formamide (DMF). Deprotection was carried out for 30 min, followed by 
3 washes with DMF. Subsequently to a Fluorenylmethyloxycarbonyl (FMOC) 
protected L-lysine was added 2.5 equivalents of O-(Benzotriazol-1-yl)-N,N,N′,N′-




methylmorpholine (NMM) in DMF. The FMOC-lysine was fully dissolved and then 
added to the arginine loaded Wang resin. The resin and the FMOC-lysine were 
stirred on a rotary shaker for >4 h followed by 3 washes with DMF and then 
testing via the Kaiser test for the presence of free amines. An absence of purple 
color was indicative of the completion of the coupling of the reaction. Subsequent 
deprotection and coupling were performed in a repetitive fashion as previously 
outlined to obtain the oligopeptide. Final deprotection was carried out for 16 h 
using a cleavage cocktail of 95% TFA: 2.5% H20:2.5% diisopropylsilane (v/v). 
The crude peptide was precipitated in cold diethylether and washed several 
times with diethylether. The final product was purified via preparative high 
pressure liquid chromatography (HPLC) at a flow rate of 15mL/min on a Zorbax 
C18 column using an isocratic flow of acetonitrile: water (20:80) with 0.1% TFA. 
The final product was tested for purity using analytical HPLC (5µm C18 at 
1mL/min flow rate) using an isocratic acetonitrile: water (20:80) with 0.1% TFA. 
The purity of the peptide was monitored by matrix absorption laser 
desorption ionization time of flight (MALDI-TOF) mass spectrometry using a 
Bruker’s ultrafleXtreme™ MALDI-TOF/TOF (AZ, USA). Samples were spotted 
using dried-droplet method. A solution of saturated 2′,4′,6′-
trihydroxyacetophenone monohydrate (THAP) in a solvent of 50:50 water: 
acetonitrile 0.1% TFA was prepared by mixing the matrix powder with 0.5 mL of 
solvent, and then centrifuged to pellet of undissolved THAP. The supernatant 
was used for sample preparation for MALDI analysis. Samples (0.5 µL of 1 




with 0.5 μL of supernatant of saturated matrix solution. Then the sample spot 
was dried, the spot was ablated with a 1 kHz smartbeam-II™ laser technology 
while the sample was simultaneously desorbed, and then accelerated into a flight 
tube. The MALDI spectrum was acquired in linear mode, at a mass range from 
1000 to 120,000 Da. 
 
A.2.2.1 FITC labeled dendrimer synthesis 
FITC labeled conjugates were prepared as reported previously.9 The 
conjugates were characterized for absence of free FITC using Superose 6 
column at a flow rate of 1 mL/min on a fast protein liquid chromatography system 
(FPLC). FITC loading was assessed by spectrophotometry as described 
previously.10 
 
A.2.2.3 Caco-2 cell culture and permeability assays 
Caco-2 cell cultures were prepared according to previously published 
methods.9,11 Cells of passage 6-16 were grown at 37°C in a tissue culture 
incubator at 5% CO2 atmosphere in air with 95% relative humidity. Dulbecco’s 
Modified Eagle’s Medium (DMEM) was used with 10% fetal bovine serum (FBS). 
The media was changed every two days until 90% confluence was attained and 
then passaged using trypsin-like enzyme (Gibcolife, NY, USA). Cells were 
passaged at least twice using trypsin-like enzyme after removal from storage in 
liquid nitrogen before being seeded onto Transwells® plates. Seeding was done 




a density of 2.6×106 cells/cm2. Cells were allowed to grow for 21-29 days before 
being used for transport experiments. Prior to permeability assays DMEM media 
was removed and transport media was applied to the apical and basolateral 
surface. Transport medium consisted of Hank’s balanced salt solution (HBSS) 
supplemented with 10 mM N-(2-hydroxyethyl)piperazine-N´-Poly(amido amine) 
(2-ethanesulfonic acid) hemisodium salt (HEPES) buffer at pH 7.4.  
Transport experiments were carried out after cells were equilibrated with 
media for 60 min. At t=0 min, the transport buffer was decanted and treatment 
was added to the apical side. FITC dextrans (5mg/mL) and FITC-G3.5 and G4 
dendrimers (0.1 mM) and various concentrations of P640 peptide were added to 
the apical side of the cells. Monolayers were then incubated at 37°C on an orbital 
shaker at 350 RPM (G76, New Brunswick, NJ, USA). 200 µL aliquots were 
sampled every 30 min from the basolateral side starting at t=0 for 120 min and 
the volume was replaced by warmed transport buffer. Temperature was 
maintained at 37°C while added media, measuring transepithelial electrical 
resistance (TEER) or sampling the solution by using a warm plate set at 37°C. 
This was done in order to obtain accurate TEER measurements due the 
temperature dependence of the measuremnt.12 TEER was measured using 
Chopstick electrode set (World Precision Instruments, FL, USA). 
Permeability of FITC-dextrans and FITC labeled dendrimers was 
quantified via fluorescence intensity appearing on the basolateral side of the cell 
monolayer. Fluorescent samples were quantified using an excitation wavelength 




M2, Molecular devices, CA, USA). All experiments included 5µL of 14C-mannitol 
as an internal control, which was quantified using liquid scintillation (LS-6000IC, 
Beckman, CA, USA). 
 
A.2.2.5 Human isolated intestinal tissue transport 
Healthy intestinal tissue was obtained from surgical patients immediately 
after removal as reported preiously.1 The tissue was macroscopically analyzed 
by a pathologist for necrotic or cancerous lesions, cut and immersed in ice cold 
oxygenated Krebs-Hensleit (KH) buffer at pH 7.4. The tissue was then 
immediately transported to the lab for mounting in Ussing chambers. Removal of 
the serosal muscle layer was performed in an oxygenated tissue dissection 
basin. After the external muscle layer was removed the epithelium was mounted 
in Ussing chambers with an exposed surface area of 0.3 cm2 (Physiolgic 
Instruments, CA, USA). Chambers were filled with 5mL of 37°C KH buffer gassed 
with 95% O2/5% CO2. Tissue was allowed to equilibrate in Ussing chambers for 
45 min to allow for achievement of maximum initial TEER. At time t=0 min 
solutions containing test probes were added to the apical side of the chambers.  
Treatments included 4 kDa FITC-labeled dextrans (FD4) at 5mg/mL and 
p640 peptide at concentration noted. All experiments included 5µL of 14C-
mannitol as a marker of paracellular permeability added to the apical side of the 
tissue. The apical and basolateral side of the chambers were sampled as 
mentioned previously.1 Fluorescence and radioactivity were quantified as above. 




Instruments, Sarasota, FL, USA) attached to AgCl electrodes (Physiologic 
Instruments, CA, USA) that were previously filled with a 3% agar solution made 
in 3M KCl. TEER measurements were taken 15, 10 and 0 min before treatment 
and every 5 min after treatment began for the initial 20 min. Following the initial 
20 min, TEER was measured every 20 min for 2 h. TEER results were analyzed 
using a student’s t-test to compare treatment values to the control. 
 
A.2.2.6 Statistical analysis 
Statistical analysis of the Papp data was compared using ANOVA, with 
Tukey’s post analysis in GraphPad® Prism (version 6.0c, CA, USA). 
 
A.3 Results and discussion 
The goal of this study was to enhance the permeability of PAMAM 
dendrimers across the intestinal mucosa. For this reason we explored the use of 
the P640 peptide. The synthesis of the P640 peptide resulted in a product with 
99% purity by HPLC analysis and a single major peak via MALDI-TOF analysis 
(Figure A.1). The product was soluble in aqueous buffers. 
TEER results from Caco-2 studies were on average 127 ± 16 Ω-cm2 at the 
beginning of the experimentation. P640 peptides caused a trending increase in 
TEER at 60 min time points. This trend later was reversed for 40mM P640 
groups where a significant decrease in TEER was noted, but not for 20 mM and 
5 mM P640 groups which still remained above control values (Figure A.2). This 






Figure A.1 MALDI-TOF spectra and HPLC analysis of P640 peptide. MALDI-
TOF analysis showed a single major peak at M/Z 1789 (A). Predicted 
molecular weight was MW 1789. HPLC chromatogram of the purified peptide 




























Figure A.2. Caco-2 TEER results with 4 kDa FITC dextran (FD4) and G3.5 
and G4 dendrimers in the presence of P640. Upper panel:  control,  FD4 
+ p640 5 mM,  FD4 + p640 20 mM,  FD4 + p640 40 mM,  Triton 
X100. Caco-2 TEER results. P640 peptides mixed with 4 kDa FITC dextran 
(FD4) caused a trending increase in TEER at 60 min time points. This trend 
was reversed at later time points for 40mM P640 groups, which were 
observed to drop in TEER (p<0.05). Lower panel:  G3.5 0.1mM.  G3.5 
0.1 mM + P640 40 mM,  G4 0.1 mM, G4 0.1 mM + P640, Triton 
X100. 40 mM. 40mM P640 peptides combined with 0.1mM PAMAM 
dendrimers caused a reduction in TEER compared to control , G4 and G3.5 
treatments (p<0.05). 


























(or permanent) reduction in TEER.13 Forty mM P640 caused a reduction in TEER 
at 120 min time points (p<0.05), but the increase in TEER for lower 
concentrations (i.e., 5 mM, 20 mM) did not match the expected results. 
Dendrimers mixed with 40mM P640 peptides caused a decrease in TEER 
(p<0.05). G3.5 dendrimer with P640 was statistically reduced compared to 0.1 
mM G3.5 dendrimers at 120 min. This reduction was also significant for P640 
with 0.1 mM G4 dendrimers, but the difference was much less. The cause of this 
variation between dendrimer G3.5 and G4 may be due to the charge induced 
TEER reduction native to G4 dendrimers. G4 dendrimers are known to have 
significant TEER reducing effects in Caco-2 cells even at 0.1 mM 
concentrations.13,14 Anionic G3.5 dendrimers at 0.1 mM concentrations have 
been observed to have lesser effect on TEER than their cationic counterparts. 
This is probably due to enhanced tissue association of cationic dendrimers with 
anionic cell surfaces.14 
Surprisingly G3.5 and G4 PAMAM dendrimer transport was reduced in the 
presence of 40 mM P640 peptides (Figure A.3). This result was true for both 
G3.5 and G4 PAMAM dendrimers, although the reduction was not statistically 
significant. This result was counterintuitive since previously it was reported that 
arginine rich peptide sequences have penetration enhancing properties.15 In 
mechanistic studies oligo arginine has been found to interact with associated 
macromolecules and this association was critical for their penetration 
enhancement.16 Surprisingly both cationic G4 PAMAM dendrimers and anionic 








Figure A.3. Caco-2 dendrimer permeability in presence of P640. G3.5 and G4 
PAMAM dendrimer transport trended toward a decreased permeability in the 
































































a lack of association for positively and negatively charged dendrimers. 
This phenomenon does not explain the reduction in transport observed. 
The reduction may be due to an unknown physiological mechanism induced by 
the P640 peptide. Potentially P640 peptides may saturate an endocytic pathway 
which PAMAM dendrimers themselves are transported by.17 It has been 
observed that endocytosis inhibitors in Caco-2 transepithelial transport studies 
inhibited dendrimer permeability across the membrane. P640 peptides may have 
similar effect by outcompeting dendrimers for endocytic vesicles. Nonetheless 
this requires further evidence since the mechanism of internalization of arginine 
rich sequences is not entirely understood and continues to be a topic of 
discussion in the scientific community.18  
Papp of 4 kDa FITC-dextrans in the presence of P640 peptides in Caco-2 
monolayers was similarly not significantly increased (Figure A.4). In spite of 40 
mM concentrations the permeability only tended to increase. This led to the 
conclusion that, at least in Caco-2 models, P640 peptides are not effective as a 
penetration enhancer. This result was confirmed by mannitol permeability results 
which showed no statistically significant increase in permeability at 40mM 
concentrations of P640 peptide with or without PAMAM dendrimers. (Figure A.5, 
A.6)  
Caco-2 models have significant differences from animal or human 
tissues.1,9,19,20 Indeed mucous layers, tissue morphology, heterogeneous cell 
types and other factors impact the permeability of PAMAM dendrimers and other 






Figure A.4. Caco-2 permeability of 4 kDa FITC dextran (FD4) in presence of 
P640. FITC dextran permeability was not statistically increased at 40mM 






















































Figure A.5. Caco-2 mannitol permeability with dendrimers and P640. Mannitol 
permeability was enhanced with the positive control Triton X100, but not in the 
presence of 0.1 mM G3.5 and G4 dendrimers or the combination of 












































































Figure A.6. Caco-2 mannitol permeability in presence of 4 kDa FITC dextrans 
(FD4) and P640. P640 did not cause a statistically significant increase in 



























































was carried out in human isolated tissues obtained from patients.  
TEER results from these studies showed no significant reduction with 
treatments up to 20 mM of P640 peptides (Figure A.7). These results correlated 
well with FITC dextran transport (Figure A.8) and mannitol transport (Figure A.9) 
which also showed no significant increase in permeability. Indeed the 
permeability of FITC dextran appeared to drop at higher concentrations of P640 
peptide indicating a lack of response to P640 peptide penetration enhancer. This 
result further confirmed the inability of P640 to mediate increased intestinal 
permeability at the dose and incubation period observe in this study. 
 
A.4  Conclusion 
 The results of this study indicate that P640 peptides do not mediate 
enhanced permeability of PAMAM dendrimers in Caco-2 cells at 120 min 
incubation times and 40 mM concentrations. Further work at longer timeframes 
may show a different response depending on the stability and uptake of these 
sequences. A greater understanding of PAMAM-peptide interactions and the 
internalization mechanisms and response time of these sequences may be 
necessary to confirm their status as a peptide penetration enhancer in Caco-2 
cells for PAMAM dendrimers.  
Furthermore the addition of P640 peptides to human isolated colonic 
epithelium did not cause a significant enhancement in 4 kDa FITC-dextran and  
mannitol permeability indicating that future work may be needed to optimize the 






Figure A.7. Isolated human colon percent TEER in presence of P640 and 4 
kDa FITC dextrans (FD4). P640 did not cause a decrease in TEER at 20 mM 
concentrations compared to control. 
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Figure A.8 Isolated human colon permeability of control (FITC) and 4 kDa 
FITC dextran (FD4) in the presence of P640 peptides. P640 showed a 



































































Figure A.9. Isolated human colon mannitol permeability in the presence of 4 
kDa FITC dextrans (FD4) and P640. The permeability of mannitol in the 





























































importantly the potential interaction of the dendrimers with the peptide 
penetration enhancers and the subsequent effect they may have on the 
permeability values observed need to be investigated. 
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